{"gene":"IL2","run_date":"2026-04-28T18:06:54","timeline":{"discoveries":[{"year":1983,"finding":"The human IL-2 cDNA encodes a 153-amino-acid polypeptide including a putative signal sequence; expression of this cDNA in COS cells produced biologically active IL-2, establishing the primary structure of the protein.","method":"cDNA cloning, sequencing, and expression in COS cells","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 — original molecular cloning with functional validation in heterologous expression system","pmids":["6403867"],"is_preprint":false},{"year":1988,"finding":"The IL-2 enhancer contains distinct antigen receptor response elements (sites A, D, E) that are required for maximal IL-2 induction; site E binds an inducible nuclear factor (NF-IL-2E) and site A binds a constitutive T-cell factor (NF-IL-2A); these elements respond to antigen receptor signals independently of PKC stimulation.","method":"Deletion mutant analysis, gel-shift/DNA binding assays, reporter gene assays in T cells","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 — multiple deletion mutants, functional reporter assays, and DNA-binding experiments in one study","pmids":["3260003"],"is_preprint":false},{"year":1991,"finding":"IL-2-deficient mice generated by gene targeting develop normally with respect to thymocyte and peripheral T-cell subset composition, but exhibit reduced polyclonal in vitro T-cell responses and dramatic changes in serum immunoglobulin isotype levels, demonstrating that IL-2 is not required for T-cell development but is required for normal peripheral immune homeostasis.","method":"Gene targeting (knockout mice), flow cytometry, in vitro proliferation assays, immunoglobulin measurement","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 — definitive in vivo loss-of-function with multiple phenotypic readouts","pmids":["1830926"],"is_preprint":false},{"year":1992,"finding":"The gamma chain (γc) of the IL-2 receptor was identified as a third subunit necessary for formation of high-affinity (αβγ heterotrimer) and intermediate-affinity (βγ heterodimer) IL-2 receptors; γc is required for IL-2-induced receptor internalization, as α and β chains alone are insufficient.","method":"cDNA cloning, receptor reconstitution in murine fibroblastoid cells, binding assays, internalization assays","journal":"Science","confidence":"High","confidence_rationale":"Tier 1 — receptor reconstitution with functional internalization assay, foundational paper","pmids":["1631559"],"is_preprint":false},{"year":1993,"finding":"The IL-2 receptor β chain (IL-2Rβ) contains at least two distinct cytoplasmic signaling regions: a 'serine-rich' region required for mitotic signaling and an 'acidic' region that physically associates with p56lck (a Src-family PTK) and activates it upon IL-2 stimulation, linking IL-2R to c-fos/c-jun and c-myc induction.","method":"IL-2Rβ cytoplasmic domain deletion mutants expressed in BAF-B03 cells, co-immunoprecipitation of p56lck, in vitro kinase assays","journal":"Annual review of immunology","confidence":"High","confidence_rationale":"Tier 1 — structure-function mutagenesis combined with biochemical co-IP and kinase assays","pmids":["8476561"],"is_preprint":false},{"year":1993,"finding":"IL-2-deficient mice develop an inflammatory bowel disease with clinical and histological similarity to ulcerative colitis, characterized by activated T and B cells, elevated immunoglobulin secretion, and anti-colon antibodies, demonstrating a primary role of IL-2 in preventing aberrant immune responses to intestinal antigens.","method":"IL-2 knockout mice, histopathology, flow cytometry, immunoglobulin assays, autoantibody detection","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 — definitive in vivo loss-of-function with multiple orthogonal readouts","pmids":["8402910"],"is_preprint":false},{"year":1994,"finding":"Jak1 and Jak3 kinases are selectively associated with IL-2 receptor subunits: Jak1 binds the serine-rich region of IL-2Rβ and Jak3 binds the C-terminal region of IL-2Rγ; both associations are required for IL-2 signaling, and Jak3-negative cells reconstituted with IL-2R components only become IL-2-responsive upon addition of Jak3 cDNA.","method":"Co-immunoprecipitation, domain-mapping with mutant receptor subunits, reconstitution in Jak3-deficient fibroblasts","journal":"Science","confidence":"High","confidence_rationale":"Tier 1 — reconstitution experiment in Jak3-deficient cells plus reciprocal co-IP, strong mechanistic evidence","pmids":["7973659"],"is_preprint":false},{"year":1999,"finding":"Stat5a and Stat5b are essential, redundant mediators of IL-2-induced T-cell proliferation and cell cycle progression; Stat5a/b double-knockout mice have peripheral T cells that fail to proliferate or express cell-cycle genes in response to IL-2, and additionally lack NK cells and develop splenomegaly resembling IL-2Rβ-deficient mice.","method":"Stat5a/b double-knockout mice, proliferation assays, gene expression analysis, flow cytometry","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 — definitive in vivo loss-of-function with multiple phenotypic readouts, replicated across multiple cytokine contexts","pmids":["10072077"],"is_preprint":false},{"year":1998,"finding":"ZEB, a zinc finger E-box binding transcription factor, represses IL-2 gene transcription in differentiated Th2 cells by binding to a negative regulatory element (NRE-A) in the IL-2 promoter.","method":"Promoter deletion analysis, gel-shift assays, reporter gene assays, Th cell differentiation experiments","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 — DNA binding demonstrated with gel-shift and promoter reporter assays in differentiated T cells","pmids":["9574548"],"is_preprint":false},{"year":2000,"finding":"IL-2 signaling activates the JAK-STAT pathway (particularly Stat5a/Stat5b) and other pathways including PI3K/AKT; negative regulation of IL-2-induced Stat5 activation is mediated by CIS/SOCS/SSI family proteins.","method":"Biochemical in vitro studies, gene-targeting analyses of Stat5a/Stat5b, cytokine signaling assays","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (biochemistry + in vivo gene targeting) across multiple labs","pmids":["10851055"],"is_preprint":false},{"year":2000,"finding":"IL-2 directly induces a unique signaling pattern in naive resting CD8+ T cells (TCR-independent): strong LCK/JAK3-dependent PI3K/AKT pathway activation with little involvement of STAT5, NF-κB, or calcineurin/NFAT, resulting in proliferation and selective expression of eomesodermin and differentiation into central memory cells.","method":"Purified naive CD8+ T cell culture with IL-2 in absence of Ag/APC, signaling pathway inhibitors, flow cytometry, adoptive transfer","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 — clean TCR-independent system with pathway inhibitors and multiple signaling readouts","pmids":["24166977"],"is_preprint":false},{"year":2001,"finding":"CD28 translocation to lipid rafts is required for costimulation of IL-2 production; all tyrosine-phosphorylated CD28 and CD28 associated with PI3K localize in lipid raft fractions, and targeting the CD28 cytoplasmic domain to lipid rafts is sufficient to induce its tyrosine phosphorylation; murine CD28 mutants defective in raft translocation lose the ability to costimulate IL-2.","method":"Lipid raft fractionation, co-immunoprecipitation, CD28 cytoplasmic domain targeting constructs, CD28 mutant analysis in Jurkat and peripheral T cells","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 — biochemical fractionation plus mutant analysis with functional IL-2 readout","pmids":["15280538"],"is_preprint":false},{"year":2004,"finding":"IL-2 suppression of hepatic CYP3A activity in vivo is not a direct effect on hepatocytes but requires Kupffer cells; in hepatocyte/Kupffer cell co-cultures, IL-2 caused 50–70% concentration-dependent suppression of CYP3A activity, whereas hepatocytes alone showed no sustained suppression.","method":"Primary human hepatocyte/Kupffer cell co-culture at physiologic ratios, CYP3A activity assays, cytokine dose-response experiments","journal":"Drug metabolism and disposition","confidence":"Medium","confidence_rationale":"Tier 2 — co-culture reconstitution system with quantitative enzyme activity assay","pmids":["14977871"],"is_preprint":false},{"year":2006,"finding":"PTEN is a negative regulator of IL-2 receptor signaling in regulatory T cells: targeted deletion of PTEN allows Treg expansion in response to IL-2 alone by de-repressing PI3K signaling downstream of the IL-2R, whereas PTEN re-expression in PTEN-deficient cells or in activated CD4+ T cells inhibits IL-2-dependent proliferation.","method":"Conditional PTEN knockout in Tregs, ex vivo IL-2-driven expansion assays, PI3K signaling measurement, suppression assays, colitis model","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 — reciprocal gain- and loss-of-function experiments with multiple functional readouts in vitro and in vivo","pmids":["16917540"],"is_preprint":false},{"year":2006,"finding":"NAB2 is induced by TCR engagement and acts as a co-activator of IL-2 transcription by binding Egr-1 at the IL-2 promoter; NAB2 overexpression enhances IL-2 production, siRNA knockdown markedly inhibits it, and ChIP confirms NAB2 recruitment to the Egr-1 binding site of the IL-2 promoter.","method":"siRNA knockdown, overexpression, chromatin immunoprecipitation (ChIP), reporter assays in T cells","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP plus bidirectional genetic manipulation with functional IL-2 readout","pmids":["17142725"],"is_preprint":false},{"year":2009,"finding":"The crystal structure of the basiliximab Fab in complex with IL-2Rα ectodomain at 2.9 Å resolution reveals that basiliximab uses all six CDR loops to engage a discontinuous epitope spanning the D1 and D2 domains of IL-2Rα, overlapping with most IL-2 contact residues and thereby sterically blocking IL-2 binding to IL-2Rα.","method":"X-ray crystallography at 2.9 Å resolution, binding affinity measurements (Kd = 0.14 nM)","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 1 — crystal structure with direct mechanistic interpretation of receptor blockade","pmids":["20032294"],"is_preprint":false},{"year":2011,"finding":"IL-2 broadly regulates helper T cell differentiation by modulating cytokine receptor expression via STAT5: IL-2 induces STAT5-dependent expression of IL-12Rβ2 and T-bet to promote Th1 differentiation, regulates Il4ra to promote Th2 differentiation, and inhibits Th17 differentiation by downregulating Il6ra and Il6st (gp130); retroviral transduction of IL-12Rβ2 or Il6st can rescue or augment the respective Th subset differentiation even when IL-2 is present or absent.","method":"IL-2 knockout T cells, retroviral transduction, cytokine receptor expression assays, STAT5 reporter, human T cell IL-2 blockade, Th subset differentiation assays","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods including KO, retroviral rescue, and human cell experiments across Th1/Th2/Th17 lineages","pmids":["21516110"],"is_preprint":false},{"year":2012,"finding":"The IL-2 'superkine' (super-2), engineered with increased IL-2Rβ binding affinity, structurally mimics the CD25-bound conformation of IL-2 by stabilizing a helix at the IL-2Rβ binding site, eliminating the functional requirement for CD25 while eliciting potent STAT5 phosphorylation, T-cell proliferation, superior CD8+ T-cell expansion, and reduced Treg expansion and pulmonary oedema compared to wild-type IL-2.","method":"In vitro evolution, crystal structures of free and receptor-bound superkine, molecular dynamics simulations, STAT5 phosphorylation assays, proliferation assays, in vivo mouse tumor models","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 — crystal structures plus molecular dynamics plus multiple functional assays in one study","pmids":["22446627"],"is_preprint":false},{"year":2016,"finding":"JAK3 kinase activity is required in two temporally distinct waves during IL-2-driven T cell proliferation: an early wave (sensitive to high JAK3 inhibitor concentrations) and a later, more JAK3-dependent second wave of STAT5 phosphorylation that is essential for cyclin expression and S-phase entry; an inhibitor-resistant JAK3 C905S mutant rescued all effects in isolated T cells and in mice.","method":"Selective covalent JAK3 inhibitor, chemical genetic rescue with JAK3 C905S mutant, STAT5 phosphorylation time-course in CD4+ T cells, cell cycle analysis","journal":"Nature chemical biology","confidence":"High","confidence_rationale":"Tier 1 — chemical genetics with inhibitor-resistant mutant rescue, time-resolved mechanistic dissection","pmids":["27018889"],"is_preprint":false},{"year":2018,"finding":"IL-2 drives CD4+ T follicular helper (TFH) versus non-TFH fate determination through differential IL-2 production at the single-cell level: IL-2 producers receiving the strongest TCR signals are fated to become TFH cells, and they deliver IL-2 in trans to nonproducer cells fated to become non-TFH cells.","method":"IL-2 reporter mice, fate-mapping, in vivo infection models, adoptive transfer experiments","journal":"Science","confidence":"High","confidence_rationale":"Tier 2 — in vivo reporter fate-mapping with mechanistic trans-delivery demonstrated","pmids":["30213884"],"is_preprint":false},{"year":2018,"finding":"IL-2 signals via the JAK1/3-STAT5 pathway to regulate T-cell metabolic programs in addition to transcriptional programs; global phosphoproteomic approaches revealed a diverse array of phosphoproteins influenced by IL-2 that shape T cell fate within each subset.","method":"Phosphoproteomics, JAK inhibitor studies, metabolic assays, T-cell subset analysis","journal":"Annual review of immunology","confidence":"Medium","confidence_rationale":"Tier 2 — phosphoproteomic approach integrated with functional metabolic assays","pmids":["29677473"],"is_preprint":false},{"year":2019,"finding":"De novo designed IL-2/IL-15 mimetics (Neoleukin-2/15, Neo-2/15) bind IL-2Rβγc with higher affinity than natural IL-2 and elicit downstream signaling without any IL-2Rα binding site; crystal structures of Neo-2/15 alone and in complex with IL-2Rβγc confirmed the designed topology, and Neo-2/15 showed superior antitumour activity in mouse models with reduced toxicity.","method":"Computational protein design, crystal structures (free and receptor-bound), binding assays, cell signaling assays, in vivo mouse melanoma and colon cancer models","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 — crystal structures plus reconstituted receptor binding plus in vivo functional validation","pmids":["30626941"],"is_preprint":false},{"year":2021,"finding":"H9T, an engineered IL-2 partial agonist, promotes CD8+ T cell expansion without terminal differentiation by generating altered (attenuated) STAT5 signaling, sustaining TCF-1 expression, and promoting mitochondrial fitness, resulting in a stem-cell-like T cell state with enhanced antitumour activity in melanoma and ALL mouse models.","method":"Engineered IL-2 variant, STAT5 signaling assays, epigenetic profiling, metabolic assays, TCF-1 expression analysis, in vivo mouse tumor models","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal mechanistic readouts (signaling, epigenetics, metabolism, in vivo efficacy) in a single well-controlled study","pmids":["34526724"],"is_preprint":false},{"year":2023,"finding":"IL-2 can signal through a non-canonical CD25–chemokine receptor pathway (alternative to the canonical JAK1/3-STAT5 axis) to promote the suppressive function of Tregs; biasing IL-2 signaling toward this alternative pathway using a specific anti-CD25 antibody, heparan sulfate, or an engineered IL-2 immunocytokine increases Treg suppressive activity and ameliorates EAE in mice.","method":"Biased anti-CD25 antibody, heparan sulfate treatment, engineered IL-2 immunocytokine, EAE mouse model, Treg suppression assays","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 — multiple tools to bias signaling pathway with functional Treg and in vivo disease readouts","pmids":["37598341"],"is_preprint":false},{"year":2024,"finding":"PGE2, via its receptors EP2 and EP4, inhibits IL-2 sensing in human CD8+ TILs by downregulating the IL-2Rγc chain, causing defective assembly of IL-2Rβ–IL-2Rγc membrane dimers; this impairs IL-2–mTOR adaptation, represses PGC1α transcription, causes oxidative stress and ferroptotic cell death in tumour-reactive TILs; blocking EP2/EP4 during TIL expansion restores IL-2 sensing and antitumour efficacy.","method":"PGE2/EP2/EP4 receptor pharmacology, IL-2Rγc surface expression measurement, IL-2Rβ–γc dimer assembly assays, mTOR signaling assays, PGC1α expression, ROS/ferroptosis assays, adoptive cell transfer mouse models","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 — mechanistically layered dissection with multiple orthogonal assays and in vivo validation","pmids":["38658764"],"is_preprint":false},{"year":2008,"finding":"IL-2Rβ chains can spontaneously form homodimers (IL-2Rβ/β) in the absence of γc, as demonstrated by co-immunoprecipitation of differentially tagged IL-2Rβ subunits and FRET between fluorescent reporter-fused IL-2Rβ chains at the cell surface; these homodimers bind IL-2 with Kd ~1 nM, similar to IL-2Rβ/γc heterodimers.","method":"Co-immunoprecipitation (HA/MYC-tagged co-transfection), FRET between ECFP/EYFP-fused IL-2Rβ, 125I-IL-2 binding assays","journal":"European cytokine network","confidence":"Medium","confidence_rationale":"Tier 2 — reciprocal co-IP plus FRET in live cells plus functional binding assay","pmids":["18299274"],"is_preprint":false},{"year":2000,"finding":"IL-2 signaling in human monocytes requires protein tyrosine kinase activity and specifically involves phosphorylation and activation of p59hck (Hck); herbimycin A (PTK inhibitor) abolishes IL-2-induced monocyte tumoricidal activity and cytokine production; IL-2 upregulates hck mRNA/protein and increases p59hck tyrosine phosphorylation and kinase activity in vitro.","method":"PTK inhibitor (herbimycin A), anti-phosphotyrosine immunoblotting, in vitro kinase assay, RT-PCR, cytotoxicity assay","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 — in vitro kinase assay plus multiple signaling readouts with pharmacological inhibition","pmids":["10779760"],"is_preprint":false},{"year":2001,"finding":"LFA-1 costimulation of IL-2 gene expression is mediated primarily through enhanced IL-2 transcription (not mRNA stabilization), as shown using an IL-2 promoter-luciferase transgenic reporter; in contrast, CD28 costimulation enhances both transcription and mRNA stability.","method":"IL-2 promoter-luciferase transgenic mice, real-time RT-PCR for mRNA stability, antigen-presenting cell lines with/without ICAM-1 or B7-1","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 — dissection of transcriptional vs. post-transcriptional mechanisms with transgenic reporter and mRNA stability assay","pmids":["11673532"],"is_preprint":false},{"year":2017,"finding":"PTEN drives Th17 cell differentiation by suppressing IL-2 production; Th17-specific Pten deletion increases IL-2 and STAT5 phosphorylation while reducing STAT3 phosphorylation, thereby inhibiting Th17 differentiation in vitro and ameliorating EAE; PTEN inhibitors phenocopy Th17 suppression.","method":"Conditional Th17-specific Pten knockout mice, IL-2 ELISA, STAT5/STAT3 phosphorylation assays, EAE model, PTEN inhibitor experiments","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 — conditional KO with in vivo disease model plus pharmacological corroboration and defined signaling mechanism","pmids":["29018045"],"is_preprint":false},{"year":2002,"finding":"CD56bright NK cells in human lymph nodes constitutively express the high-affinity IL-2 receptor and respond to endogenous T cell-derived IL-2 by secreting IFN-γ, establishing a direct mechanistic link between adaptive T cell-derived IL-2 and innate NK cell cytokine production.","method":"In situ hybridization, flow cytometry, lymph node NK cell isolation, IL-2 neutralization experiments, IFN-γ assays","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 — direct neutralization of endogenous IL-2 with functional IFN-γ readout in primary human cells","pmids":["12480696"],"is_preprint":false}],"current_model":"IL-2 is a secreted cytokine whose primary structure was established by cDNA cloning; it binds a trimeric receptor (IL-2Rα/β/γc) where γc is required for internalization, Jak1 associates with the serine-rich region of IL-2Rβ and Jak3 with IL-2Rγc to activate STAT5 (redundantly via Stat5a/b) and PI3K/AKT signaling; STAT5 then broadly regulates helper T-cell fate by modulating cytokine receptor expression (IL-12Rβ2, IL-4Rα, gp130), while negative regulators including SOCS proteins, PTEN, ZEB, and PGE2 (acting through EP2/EP4-mediated downregulation of IL-2Rγc) control the magnitude of IL-2 signaling; in vivo, IL-2 is essential for regulatory T-cell development and peripheral tolerance (not T-cell thymic development), and engineered IL-2 variants with altered receptor subunit affinities selectively bias signaling toward CD8+ effector T cells or Tregs for therapeutic purposes."},"narrative":{"teleology":[{"year":1983,"claim":"Molecular cloning of the human IL-2 cDNA established the primary structure of the protein and proved that the cloned sequence was sufficient for biological activity, enabling all subsequent structure–function work.","evidence":"cDNA cloning, sequencing, and functional expression in COS cells","pmids":["6403867"],"confidence":"High","gaps":["post-translational modifications not characterized","receptor identity unknown at this point"]},{"year":1988,"claim":"Identification of distinct antigen receptor response elements (sites A, D, E) and their cognate transcription factors in the IL-2 enhancer revealed how TCR engagement transcriptionally activates IL-2 independently of PKC, establishing the promoter architecture governing inducible IL-2 expression.","evidence":"Deletion mutant analysis, gel-shift assays, and reporter gene assays in T cells","pmids":["3260003"],"confidence":"High","gaps":["identity of all trans-acting factors not resolved","chromatin-level regulation not addressed"]},{"year":1991,"claim":"IL-2 knockout mice demonstrated that IL-2 is dispensable for thymic T-cell development but essential for peripheral immune homeostasis, reframing IL-2 from a T-cell growth factor to a tolerance regulator.","evidence":"Gene-targeted IL-2-null mice with flow cytometry, proliferation assays, and immunoglobulin measurements","pmids":["1830926"],"confidence":"High","gaps":["mechanism of peripheral tolerance breakdown not defined","contribution of Tregs not yet recognized"]},{"year":1992,"claim":"Discovery of γc as the third IL-2R subunit resolved how high-affinity and intermediate-affinity receptor forms assemble and showed that γc is required for ligand-induced receptor internalization, completing the receptor architecture.","evidence":"cDNA cloning, receptor reconstitution in fibroblastoid cells, binding and internalization assays","pmids":["1631559"],"confidence":"High","gaps":["signaling events downstream of γc not yet mapped","shared use of γc by other cytokines not explored here"]},{"year":1993,"claim":"Mapping of IL-2Rβ cytoplasmic domains identified a serine-rich region for mitogenic signaling and an acidic region that recruits p56lck, linking IL-2R to Src-family kinase activation and immediate-early gene induction, while IL-2-null mice developed ulcerative colitis-like disease, cementing IL-2's role in mucosal tolerance.","evidence":"IL-2Rβ deletion mutants with co-IP and kinase assays; IL-2 KO mice with histopathology and autoantibody detection","pmids":["8476561","8402910"],"confidence":"High","gaps":["identity of kinases directly activated by the serine-rich region not yet known","Treg mechanism of tolerance not established"]},{"year":1994,"claim":"Demonstrating that Jak1 binds IL-2Rβ and Jak3 binds γc—and that Jak3 reconstitution restores IL-2 responsiveness—established the proximal kinase pair that initiates IL-2 signaling cascades.","evidence":"Co-IP domain mapping plus reconstitution of Jak3 in Jak3-deficient fibroblasts","pmids":["7973659"],"confidence":"High","gaps":["temporal dynamics of Jak1 vs Jak3 activation unclear","downstream substrate hierarchy not defined"]},{"year":1998,"claim":"Identification of ZEB as a repressor of IL-2 transcription in Th2 cells via the NRE-A element revealed a lineage-specific negative regulatory mechanism silencing IL-2 during T-helper differentiation.","evidence":"Promoter deletion analysis, gel-shift assays, reporter assays in differentiated Th cells","pmids":["9574548"],"confidence":"Medium","gaps":["in vivo relevance of ZEB-mediated repression not confirmed with knockout","interaction with other promoter-bound factors not mapped"]},{"year":1999,"claim":"Stat5a/b double-knockout mice proved that STAT5 is the essential, redundant downstream effector of IL-2-induced T-cell proliferation and cell-cycle entry, phenocopying IL-2Rβ deficiency.","evidence":"Stat5a/b double-KO mice with proliferation assays, gene expression analysis, and flow cytometry","pmids":["10072077"],"confidence":"High","gaps":["STAT5-independent IL-2 signaling outputs not fully cataloged","direct STAT5 transcriptional targets in T cells not genome-wide mapped at this point"]},{"year":2000,"claim":"Integration of biochemical and genetic data consolidated the JAK-STAT5 and PI3K/AKT axes as the principal IL-2 signaling pathways, with CIS/SOCS proteins identified as negative feedback regulators of STAT5 activation.","evidence":"Biochemical signaling assays, gene-targeting analyses, cytokine dose-response studies","pmids":["10851055"],"confidence":"High","gaps":["relative contribution of each SOCS family member not individually resolved","metabolic consequences of PI3K/AKT activation downstream of IL-2 not yet defined"]},{"year":2006,"claim":"PTEN was established as a key negative regulator of IL-2R-driven PI3K signaling in Tregs, with its deletion enabling IL-2-alone-driven Treg expansion, revealing a tunable brake on the IL-2/PI3K/AKT axis that governs Treg homeostasis.","evidence":"Conditional PTEN KO in Tregs with reciprocal gain/loss-of-function experiments, PI3K signaling, and in vivo colitis model","pmids":["16917540"],"confidence":"High","gaps":["PTEN interaction with SOCS-mediated STAT5 regulation not addressed","Treg-specific vs pan-T-cell PTEN effects not fully delineated"]},{"year":2011,"claim":"IL-2 was shown to broadly control helper T-cell fate by STAT5-dependent modulation of cytokine receptor chains (IL-12Rβ2, IL-4Rα, gp130), promoting Th1 and Th2 while suppressing Th17 differentiation—redefining IL-2 as a master regulator of T-helper lineage commitment.","evidence":"IL-2 KO T cells, retroviral transduction rescue, cytokine receptor expression profiling, human T-cell IL-2 blockade","pmids":["21516110"],"confidence":"High","gaps":["epigenetic mechanisms linking STAT5 to receptor gene regulation not resolved","quantitative thresholds of IL-2 needed for each lineage decision unknown"]},{"year":2012,"claim":"Structural and functional characterization of 'super-2' (an engineered high-affinity IL-2Rβ binder) demonstrated that stabilizing the CD25-bound conformation of IL-2 eliminates CD25 dependence, biasing signaling toward CD8+ effector expansion over Treg expansion—establishing the principle of receptor-biased IL-2 engineering.","evidence":"Crystal structures of free and receptor-bound superkine, molecular dynamics, signaling and proliferation assays, in vivo tumor models","pmids":["22446627"],"confidence":"High","gaps":["long-term immunological consequences of bypassing CD25 not assessed","toxicity mechanisms beyond pulmonary edema not explored"]},{"year":2016,"claim":"Chemical genetic dissection revealed two temporally distinct JAK3-dependent waves of STAT5 phosphorylation during IL-2-driven proliferation, with the second wave essential for cyclin expression and S-phase entry, refining the kinetic model of IL-2 signaling.","evidence":"Covalent JAK3 inhibitor with inhibitor-resistant C905S mutant rescue, time-resolved STAT5 phosphorylation, cell-cycle analysis","pmids":["27018889"],"confidence":"High","gaps":["molecular basis for differential JAK3 sensitivity of the two waves unclear","whether this biphasic pattern applies to all T-cell subsets untested"]},{"year":2018,"claim":"In vivo fate-mapping showed that IL-2-producing CD4+ T cells receiving the strongest TCR signals become TFH cells, while non-producers receiving IL-2 in trans become non-TFH effectors, establishing a paracrine delivery model for IL-2-driven fate divergence.","evidence":"IL-2 reporter mice, fate-mapping, infection models, adoptive transfer","pmids":["30213884"],"confidence":"High","gaps":["molecular mechanism of trans-delivery (synapse vs diffusion) not resolved","generalizability beyond infection models not tested"]},{"year":2019,"claim":"De novo computational design of Neo-2/15, a synthetic IL-2/IL-15 mimetic with no sequence or structural homology to natural cytokines, demonstrated that IL-2Rβγc engagement alone—without any IL-2Rα contact—suffices for potent signaling and superior antitumor activity with reduced toxicity.","evidence":"Crystal structures (free and receptor-bound), binding assays, cell signaling, mouse melanoma and colon cancer models","pmids":["30626941"],"confidence":"High","gaps":["human clinical translation and immunogenicity not assessed","whether Neo-2/15 engages non-canonical IL-2 signaling pathways unknown"]},{"year":2021,"claim":"The IL-2 partial agonist H9T showed that attenuated STAT5 signaling preserves TCF-1 expression and mitochondrial fitness in CD8+ T cells, generating stem-cell-like effectors with enhanced antitumor activity—demonstrating that signal strength, not just pathway identity, determines T-cell differentiation outcome.","evidence":"Engineered IL-2 variant with STAT5 signaling, epigenetic profiling, metabolic assays, in vivo tumor models","pmids":["34526724"],"confidence":"High","gaps":["epigenetic mechanisms linking attenuated STAT5 to TCF-1 maintenance not defined","durability of stem-like state after withdrawal of H9T not tested"]},{"year":2023,"claim":"Discovery of a non-canonical IL-2 signaling mode through CD25 and a chemokine receptor pathway—distinct from JAK1/3-STAT5—that specifically enhances Treg suppressive function revealed an unexpected layer of signaling complexity exploitable for selective immunomodulation.","evidence":"Biased anti-CD25 antibody, heparan sulfate treatment, engineered IL-2 immunocytokine, EAE model, Treg suppression assays","pmids":["37598341"],"confidence":"Medium","gaps":["identity and mechanism of the chemokine receptor component not fully defined","whether this pathway operates in human Tregs in vivo not demonstrated","independent replication needed"]},{"year":2024,"claim":"PGE2 was shown to impair IL-2 sensing in tumor-infiltrating CD8+ T cells by EP2/EP4-mediated downregulation of γc, disrupting IL-2Rβ–γc dimer assembly and causing mTOR-PGC1α failure, oxidative stress, and ferroptosis—linking the tumor prostaglandin microenvironment directly to IL-2 signaling resistance.","evidence":"EP2/EP4 pharmacology, γc surface expression and dimer assembly assays, mTOR/PGC1α/ROS/ferroptosis assays, adoptive cell transfer models","pmids":["38658764"],"confidence":"High","gaps":["whether PGE2-driven γc loss affects other γc-dependent cytokines in TILs not tested","mechanism of EP2/EP4-mediated γc transcriptional or post-translational downregulation not resolved"]},{"year":null,"claim":"Key open questions include: (1) the structural and kinetic basis for non-canonical IL-2 signaling through CD25/chemokine receptor pathways; (2) how IL-2 signal strength is decoded epigenetically to produce distinct T-cell differentiation and metabolic programs; and (3) whether therapeutic IL-2 variants can be designed to independently tune STAT5 vs PI3K/AKT vs non-canonical outputs for precision immunotherapy.","evidence":"","pmids":[],"confidence":"Low","gaps":["no structural model of the non-canonical signaling complex exists","genome-wide STAT5 target gene sets in specific T-cell subsets at defined IL-2 concentrations not available","clinical translation data for biased IL-2 variants remain limited"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[0,3,17,21]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[0,19]}],"pathway":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[1,8,14]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[2,5,7,16,19,24]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[6,9,13,17,18,22,23]}],"complexes":[],"partners":["IL2RA","IL2RB","IL2RG","JAK1","JAK3","STAT5A","STAT5B","PTEN"],"other_free_text":[]},"mechanistic_narrative":"IL-2 is a secreted cytokine that orchestrates peripheral immune homeostasis by driving T-cell proliferation, directing helper T-cell fate decisions, sustaining regulatory T-cell function, and bridging adaptive and innate immunity through NK cell activation. IL-2 signals through a trimeric receptor (IL-2Rα/β/γc), where γc is essential for receptor internalization and high-affinity binding [PMID:1631559]; ligand engagement activates Jak1 (via the IL-2Rβ serine-rich region) and Jak3 (via γc) to phosphorylate STAT5a/b redundantly, which in turn modulates cytokine receptor expression (IL-12Rβ2, IL-4Rα, gp130) to broadly regulate Th1, Th2, and Th17 lineage commitment [PMID:7973659, PMID:10072077, PMID:21516110]. IL-2 also activates PI3K/AKT signaling, negatively regulated by PTEN and SOCS/CIS family proteins, and signal strength is tuned by PGE2-mediated downregulation of γc on tumor-infiltrating lymphocytes, linking prostaglandin metabolism to IL-2 sensing and ferroptotic vulnerability [PMID:10851055, PMID:16917540, PMID:38658764]. IL-2-deficient mice are not impaired in thymic T-cell development but develop inflammatory bowel disease resembling ulcerative colitis, establishing IL-2 as essential for peripheral tolerance rather than lymphocyte ontogeny [PMID:1830926, PMID:8402910]."},"prefetch_data":{"uniprot":{"accession":"P60568","full_name":"Interleukin-2","aliases":["T-cell growth factor","TCGF"],"length_aa":153,"mass_kda":17.6,"function":"Cytokine produced by activated CD4-positive helper T-cells and to a lesser extend activated CD8-positive T-cells and natural killer (NK) cells that plays pivotal roles in the immune response and tolerance (PubMed:6438535). Binds to a receptor complex composed of either the high-affinity trimeric IL-2R (IL2RA/CD25, IL2RB/CD122 and IL2RG/CD132) or the low-affinity dimeric IL-2R (IL2RB and IL2RG) (PubMed:16293754, PubMed:16477002). Interaction with the receptor leads to oligomerization and conformation changes in the IL-2R subunits resulting in downstream signaling starting with phosphorylation of JAK1 and JAK3 (PubMed:7973659). In turn, JAK1 and JAK3 phosphorylate the receptor to form a docking site leading to the phosphorylation of several substrates including STAT5 (PubMed:8580378). This process leads to activation of several pathways including STAT, phosphoinositide-3-kinase/PI3K and mitogen-activated protein kinase/MAPK pathways (PubMed:25142963). Functions as a T-cell growth factor and can increase NK-cell cytolytic activity as well (PubMed:6608729). Promotes strong proliferation of activated B-cells and subsequently immunoglobulin production (PubMed:6438535). Plays a pivotal role in regulating the adaptive immune system by controlling the survival and proliferation of regulatory T-cells, which are required for the maintenance of immune tolerance. Moreover, participates in the differentiation and homeostasis of effector T-cell subsets, including Th1, Th2, Th17 as well as memory CD8-positive T-cells","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/P60568/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/IL2","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/IL2","total_profiled":1310},"omim":[{"mim_id":"621234","title":"ICHAD SYNDROME; ICHAD","url":"https://www.omim.org/entry/621234"},{"mim_id":"621233","title":"IMMUNODYSREGULATION WITH VARIABLE IMMUNODEFICIENCY AND AUTOIMMUNITY; IMDIA","url":"https://www.omim.org/entry/621233"},{"mim_id":"621185","title":"HOUGE-JANSSENS SYNDROME 4; HJS4","url":"https://www.omim.org/entry/621185"},{"mim_id":"620787","title":"T-CELL ACTIVATION INHIBITOR, MITOCHONDRIAL; TCAIM","url":"https://www.omim.org/entry/620787"},{"mim_id":"620430","title":"AUTOIMMUNE DISEASE, MULTISYSTEM, INFANTILE-ONSET, 3; ADMIO3","url":"https://www.omim.org/entry/620430"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Not detected","tissue_distribution":"Not detected","driving_tissues":[],"url":"https://www.proteinatlas.org/search/IL2"},"hgnc":{"alias_symbol":["IL-2","TCGF"],"prev_symbol":[]},"alphafold":{"accession":"P60568","domains":[{"cath_id":"1.20.1250.10","chopping":"26-151","consensus_level":"high","plddt":89.9321,"start":26,"end":151}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P60568","model_url":"https://alphafold.ebi.ac.uk/files/AF-P60568-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P60568-F1-predicted_aligned_error_v6.png","plddt_mean":84.12},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=IL2","jax_strain_url":"https://www.jax.org/strain/search?query=IL2"},"sequence":{"accession":"P60568","fasta_url":"https://rest.uniprot.org/uniprotkb/P60568.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P60568/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P60568"}},"corpus_meta":[{"pmid":"24907378","id":"PMC_24907378","title":"IL-2: the first effective immunotherapy for human cancer.","date":"2014","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/24907378","citation_count":974,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1631559","id":"PMC_1631559","title":"Cloning of the gamma chain of the human IL-2 receptor.","date":"1992","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/1631559","citation_count":879,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15343366","id":"PMC_15343366","title":"Tolerance, not immunity, crucially depends on IL-2.","date":"2004","source":"Nature reviews. Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/15343366","citation_count":632,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30089912","id":"PMC_30089912","title":"Biology and regulation of IL-2: from molecular mechanisms to human therapy.","date":"2018","source":"Nature reviews. Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30089912","citation_count":505,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29980618","id":"PMC_29980618","title":"Revisiting IL-2: Biology and therapeutic prospects.","date":"2018","source":"Science immunology","url":"https://pubmed.ncbi.nlm.nih.gov/29980618","citation_count":497,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7546397","id":"PMC_7546397","title":"Transcriptional regulation of the IL-2 gene.","date":"1995","source":"Current opinion in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/7546397","citation_count":444,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15034008","id":"PMC_15034008","title":"IL-2, regulatory T cells, and tolerance.","date":"2004","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/15034008","citation_count":435,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30626941","id":"PMC_30626941","title":"De novo design of potent and selective mimics of IL-2 and IL-15.","date":"2019","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/30626941","citation_count":412,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27471638","id":"PMC_27471638","title":"Role of IL-2 in cancer immunotherapy.","date":"2016","source":"Oncoimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/27471638","citation_count":401,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21516110","id":"PMC_21516110","title":"Modulation of cytokine receptors by IL-2 broadly regulates differentiation into helper T cell lineages.","date":"2011","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/21516110","citation_count":389,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35217787","id":"PMC_35217787","title":"Engineering IL-2 for immunotherapy of autoimmunity and cancer.","date":"2022","source":"Nature reviews. Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35217787","citation_count":280,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10851055","id":"PMC_10851055","title":"The role of Stat5a and Stat5b in signaling by IL-2 family cytokines.","date":"2000","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/10851055","citation_count":280,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25200249","id":"PMC_25200249","title":"The IL-2 cytokine family in cancer immunotherapy.","date":"2014","source":"Cytokine & growth factor reviews","url":"https://pubmed.ncbi.nlm.nih.gov/25200249","citation_count":217,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30213884","id":"PMC_30213884","title":"Differential IL-2 expression defines developmental fates of follicular versus nonfollicular helper T cells.","date":"2018","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/30213884","citation_count":204,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16365415","id":"PMC_16365415","title":"IL-27 limits IL-2 production during Th1 differentiation.","date":"2006","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/16365415","citation_count":174,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7602120","id":"PMC_7602120","title":"IL-2 knockout recipient mice reject islet cell allografts.","date":"1995","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/7602120","citation_count":163,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33266177","id":"PMC_33266177","title":"Immunomodulatory Effects of IL-2 and IL-15; Implications for Cancer Immunotherapy.","date":"2020","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/33266177","citation_count":157,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38658764","id":"PMC_38658764","title":"PGE2 inhibits TIL expansion by disrupting IL-2 signalling and mitochondrial function.","date":"2024","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/38658764","citation_count":153,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34526724","id":"PMC_34526724","title":"An engineered IL-2 partial agonist promotes CD8+ T cell stemness.","date":"2021","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/34526724","citation_count":145,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16917540","id":"PMC_16917540","title":"PTEN inhibits IL-2 receptor-mediated expansion of CD4+ CD25+ Tregs.","date":"2006","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/16917540","citation_count":139,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1375246","id":"PMC_1375246","title":"Substance P enhances IL-2 expression in activated human T cells.","date":"1992","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/1375246","citation_count":128,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18475497","id":"PMC_18475497","title":"Biological significance of soluble IL-2 receptor.","date":"1993","source":"Mediators of inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/18475497","citation_count":125,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33868284","id":"PMC_33868284","title":"Low-Dose IL-2 Therapy in Autoimmune and Rheumatic Diseases.","date":"2021","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33868284","citation_count":123,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30380412","id":"PMC_30380412","title":"Differential Roles of IL-2 Signaling in Developing versus Mature Tregs.","date":"2018","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/30380412","citation_count":118,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29527328","id":"PMC_29527328","title":"Targeting IL-2: an unexpected effect in treating immunological diseases.","date":"2018","source":"Signal transduction and targeted therapy","url":"https://pubmed.ncbi.nlm.nih.gov/29527328","citation_count":118,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9620644","id":"PMC_9620644","title":"Signaling from the IL-2 receptor to the nucleus.","date":"1997","source":"Cytokine & growth factor reviews","url":"https://pubmed.ncbi.nlm.nih.gov/9620644","citation_count":117,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33158368","id":"PMC_33158368","title":"Engineering IL-2 to Give New Life to T Cell Immunotherapy.","date":"2020","source":"Annual review of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33158368","citation_count":114,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32817295","id":"PMC_32817295","title":"An IL-2 mutein engineered to promote expansion of regulatory T cells arrests ongoing autoimmunity in mice.","date":"2020","source":"Science immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32817295","citation_count":111,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9794841","id":"PMC_9794841","title":"The use of antibodies against the IL-2 receptor in transplantation.","date":"1998","source":"Current opinion in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/9794841","citation_count":106,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29443657","id":"PMC_29443657","title":"IL-2 and Beyond in Cancer Immunotherapy.","date":"2018","source":"Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research","url":"https://pubmed.ncbi.nlm.nih.gov/29443657","citation_count":104,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29522246","id":"PMC_29522246","title":"Biology of IL-2 and its therapeutic modulation: Mechanisms and strategies.","date":"2018","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/29522246","citation_count":103,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29854806","id":"PMC_29854806","title":"Prospects of IL-2 in Cancer Immunotherapy.","date":"2018","source":"BioMed research international","url":"https://pubmed.ncbi.nlm.nih.gov/29854806","citation_count":102,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22951308","id":"PMC_22951308","title":"Application of IL-2 therapy to target T regulatory cell function.","date":"2012","source":"Trends in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/22951308","citation_count":102,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8335921","id":"PMC_8335921","title":"Role and effect of IL-2 in experimental visceral leishmaniasis.","date":"1993","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/8335921","citation_count":92,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11290772","id":"PMC_11290772","title":"ICOS costimulation requires IL-2 and can be prevented by CTLA-4 engagement.","date":"2001","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/11290772","citation_count":87,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"6601512","id":"PMC_6601512","title":"Growth inhibition of an MC-induced mouse sarcoma by TCGF (IL 2)-containing preparations. Preliminary report.","date":"1983","source":"Cancer immunology, immunotherapy : CII","url":"https://pubmed.ncbi.nlm.nih.gov/6601512","citation_count":87,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14977871","id":"PMC_14977871","title":"Kupffer cell-mediated IL-2 suppression of CYP3A activity in human hepatocytes.","date":"2004","source":"Drug metabolism and disposition: the biological fate of chemicals","url":"https://pubmed.ncbi.nlm.nih.gov/14977871","citation_count":83,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18723131","id":"PMC_18723131","title":"Transcriptional regulation of IL-2 in health and autoimmunity.","date":"2008","source":"Autoimmunity reviews","url":"https://pubmed.ncbi.nlm.nih.gov/18723131","citation_count":80,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15102596","id":"PMC_15102596","title":"Application of IL-2 and other cytokines in renal cancer.","date":"2004","source":"Expert opinion on biological therapy","url":"https://pubmed.ncbi.nlm.nih.gov/15102596","citation_count":79,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8977230","id":"PMC_8977230","title":"Beryllium induces IL-2 and IFN-gamma in berylliosis.","date":"1997","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/8977230","citation_count":77,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26936133","id":"PMC_26936133","title":"Itk is required for Th9 differentiation via TCR-mediated induction of IL-2 and IRF4.","date":"2016","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/26936133","citation_count":77,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27018889","id":"PMC_27018889","title":"Essential biphasic role for JAK3 catalytic activity in IL-2 receptor signaling.","date":"2016","source":"Nature chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/27018889","citation_count":76,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2971729","id":"PMC_2971729","title":"Defective production of and response to IL-2 in acute human falciparum malaria.","date":"1988","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/2971729","citation_count":76,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12220550","id":"PMC_12220550","title":"IL-2 and autoimmune disease.","date":"2002","source":"Cytokine & growth factor reviews","url":"https://pubmed.ncbi.nlm.nih.gov/12220550","citation_count":72,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1730872","id":"PMC_1730872","title":"IL-2 induces IL-6 production in human monocytes.","date":"1992","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/1730872","citation_count":72,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10820393","id":"PMC_10820393","title":"Expression of functional IL-2 receptors on mature splenic dendritic cells.","date":"2000","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/10820393","citation_count":67,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2305833","id":"PMC_2305833","title":"IL-2 mRNA expression in Tac-positive malignant lymphomas.","date":"1990","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/2305833","citation_count":66,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16459146","id":"PMC_16459146","title":"The dichotomous role of IL-2: tolerance versus immunity.","date":"2006","source":"Trends in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16459146","citation_count":64,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20351308","id":"PMC_20351308","title":"TRAF6 inhibits Th17 differentiation and TGF-beta-mediated suppression of IL-2.","date":"2010","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/20351308","citation_count":63,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29018045","id":"PMC_29018045","title":"PTEN drives Th17 cell differentiation by preventing IL-2 production.","date":"2017","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/29018045","citation_count":57,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"3872165","id":"PMC_3872165","title":"Tumour inhibitory effects of TCGF/IL-2/-containing preparations.","date":"1985","source":"Cancer immunology, immunotherapy : CII","url":"https://pubmed.ncbi.nlm.nih.gov/3872165","citation_count":56,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36316485","id":"PMC_36316485","title":"A split, conditionally active mimetic of IL-2 reduces the toxicity of systemic cytokine therapy.","date":"2022","source":"Nature biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/36316485","citation_count":55,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9574548","id":"PMC_9574548","title":"Transcriptional repression of the IL-2 gene in Th cells by ZEB.","date":"1998","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/9574548","citation_count":55,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2833533","id":"PMC_2833533","title":"Beta-endorphin enhances interleukin-2 (IL-2) production in murine lymphocytes.","date":"1988","source":"Journal of neuroimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/2833533","citation_count":52,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2033254","id":"PMC_2033254","title":"Superinduction of IL-2 gene transcription in the presence of cycloheximide.","date":"1991","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/2033254","citation_count":52,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23499139","id":"PMC_23499139","title":"IL-2 therapy in type 1 diabetes: \"Trials\" and tribulations.","date":"2013","source":"Clinical immunology (Orlando, Fla.)","url":"https://pubmed.ncbi.nlm.nih.gov/23499139","citation_count":51,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27650575","id":"PMC_27650575","title":"Selective targeting of IL-2 to NKG2D bearing cells for improved immunotherapy.","date":"2016","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/27650575","citation_count":51,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18468581","id":"PMC_18468581","title":"Regulatory mechanisms of IL-2 and IFNgamma suppression by quercetin in T helper cells.","date":"2008","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/18468581","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8317884","id":"PMC_8317884","title":"Expression of IL-2 receptors in human melanoma cells.","date":"1993","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/8317884","citation_count":47,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24166977","id":"PMC_24166977","title":"Unique features of naive CD8+ T cell activation by IL-2.","date":"2013","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/24166977","citation_count":47,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19038244","id":"PMC_19038244","title":"Andrographolide reduces IL-2 production in T-cells by interfering with NFAT and MAPK activation.","date":"2008","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/19038244","citation_count":46,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9973402","id":"PMC_9973402","title":"Evidence for repression of IL-2 gene activation in anergic T cells.","date":"1999","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/9973402","citation_count":45,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16517754","id":"PMC_16517754","title":"Sensitization of IL-2 signaling through TLR-7 enhances B lymphoma cell immunogenicity.","date":"2006","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/16517754","citation_count":44,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18421536","id":"PMC_18421536","title":"Attenuated Salmonella typhimurium with IL-2 gene reduces pulmonary metastases in murine osteosarcoma.","date":"2008","source":"Clinical orthopaedics and related research","url":"https://pubmed.ncbi.nlm.nih.gov/18421536","citation_count":44,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29017923","id":"PMC_29017923","title":"Lysophosphatidylserine suppresses IL-2 production in CD4 T cells through LPS3/GPR174.","date":"2017","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/29017923","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24586481","id":"PMC_24586481","title":"Inflammation enhances IL-2 driven differentiation of cytolytic CD4 T cells.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24586481","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23670972","id":"PMC_23670972","title":"Limitations of IL-2 and rapamycin in immunotherapy of type 1 diabetes.","date":"2013","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/23670972","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35699942","id":"PMC_35699942","title":"Context-dependent effects of IL-2 rewire immunity into distinct cellular circuits.","date":"2022","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35699942","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9545944","id":"PMC_9545944","title":"Detection of human IL-2 in normal and inflamed dental pulps.","date":"1997","source":"Journal of endodontics","url":"https://pubmed.ncbi.nlm.nih.gov/9545944","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2143208","id":"PMC_2143208","title":"IL-2 enhances c-fms expression in human monocytes.","date":"1990","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/2143208","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10725707","id":"PMC_10725707","title":"Regulation of lymphoid homeostasis by IL-2 receptor signals in vivo.","date":"2000","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/10725707","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29256180","id":"PMC_29256180","title":"IL-2 mediates NK cell proliferation but not hyperactivity.","date":"2018","source":"Immunologic research","url":"https://pubmed.ncbi.nlm.nih.gov/29256180","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28104702","id":"PMC_28104702","title":"IL-2 promotes early Treg reconstitution after allogeneic hematopoietic cell transplantation.","date":"2017","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/28104702","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27283871","id":"PMC_27283871","title":"Restoring regulation - IL-2 therapy in systemic lupus erythematosus.","date":"2016","source":"Expert review of clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/27283871","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27293315","id":"PMC_27293315","title":"Pleiotropic Effects of IL-2 on Cancer: Its Role in Cervical Cancer.","date":"2016","source":"Mediators of inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/27293315","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17142725","id":"PMC_17142725","title":"Cutting Edge: TCR-induced NAB2 enhances T cell function by coactivating IL-2 transcription.","date":"2006","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/17142725","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28551309","id":"PMC_28551309","title":"Ontak-like human IL-2 fusion toxin.","date":"2017","source":"Journal of immunological methods","url":"https://pubmed.ncbi.nlm.nih.gov/28551309","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2394465","id":"PMC_2394465","title":"Interaction between endogenous opioids and IL-2 on PHA-stimulated human lymphocytes.","date":"1990","source":"Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/2394465","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"6178678","id":"PMC_6178678","title":"The in vivo effects of interleukin 2 (TCGF).","date":"1982","source":"Immunobiology","url":"https://pubmed.ncbi.nlm.nih.gov/6178678","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26529512","id":"PMC_26529512","title":"Functional Modulation of Regulatory T Cells by IL-2.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26529512","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8419486","id":"PMC_8419486","title":"IL-2 contributes to the IL-5 response in granulomas from mice infected with Schistosoma mansoni.","date":"1993","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/8419486","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11673532","id":"PMC_11673532","title":"Molecular mechanisms of IL-2 gene regulation following costimulation through LFA-1.","date":"2001","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/11673532","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27734211","id":"PMC_27734211","title":"Low-Dose IL-2 in the Treatment of Lupus.","date":"2016","source":"Current rheumatology reports","url":"https://pubmed.ncbi.nlm.nih.gov/27734211","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20032294","id":"PMC_20032294","title":"Structural basis for the blockage of IL-2 signaling by therapeutic antibody basiliximab.","date":"2009","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/20032294","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9257820","id":"PMC_9257820","title":"Cot kinase regulation of IL-2 production in Jurkat T cells.","date":"1997","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/9257820","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21876034","id":"PMC_21876034","title":"IL-2 regulates expression of C-MAF in human CD4 T cells.","date":"2011","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/21876034","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9545572","id":"PMC_9545572","title":"The development of IL-2 conjugated liposomes for therapeutic purposes.","date":"1998","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/9545572","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7635184","id":"PMC_7635184","title":"Does thalidomide affect IL-2 response and production?","date":"1995","source":"Experimental hematology","url":"https://pubmed.ncbi.nlm.nih.gov/7635184","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33828163","id":"PMC_33828163","title":"Life-extended glycosylated IL-2 promotes Treg induction and suppression of autoimmunity.","date":"2021","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/33828163","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15953676","id":"PMC_15953676","title":"Fractalkine gene therapy for neuroblastoma is more effective in combination with targeted IL-2.","date":"2005","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/15953676","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21030882","id":"PMC_21030882","title":"Additive melanoma suppression with intralesional phospholipid-conjugated TLR7 agonists and systemic IL-2.","date":"2011","source":"Melanoma research","url":"https://pubmed.ncbi.nlm.nih.gov/21030882","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34130625","id":"PMC_34130625","title":"LncRNA H19 induces immune dysregulation of BMMSCs, at least partly, by inhibiting IL-2 production.","date":"2021","source":"Molecular medicine (Cambridge, Mass.)","url":"https://pubmed.ncbi.nlm.nih.gov/34130625","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10779760","id":"PMC_10779760","title":"IL-2 signaling in human monocytes involves the phosphorylation and activation of p59hck.","date":"2000","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/10779760","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20458706","id":"PMC_20458706","title":"Revisiting the role of IL-2 in autoimmunity.","date":"2010","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/20458706","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15280538","id":"PMC_15280538","title":"Translocation of CD28 to lipid rafts and costimulation of IL-2.","date":"2004","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/15280538","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11418624","id":"PMC_11418624","title":"Cutting edge: Ly49A inhibits TCR/CD3-induced apoptosis and IL-2 secretion.","date":"2001","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/11418624","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37598341","id":"PMC_37598341","title":"IL-2 can signal via chemokine receptors to promote regulatory T cells' suppressive function.","date":"2023","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/37598341","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11318598","id":"PMC_11318598","title":"Defective apoptosis in lymphocytes and the role of IL-2 in autoimmune hematologic cytopenias.","date":"2001","source":"Clinical immunology (Orlando, Fla.)","url":"https://pubmed.ncbi.nlm.nih.gov/11318598","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18299274","id":"PMC_18299274","title":"Human IL-Rbeta chains form IL-2 binding homodimers.","date":"2008","source":"European cytokine network","url":"https://pubmed.ncbi.nlm.nih.gov/18299274","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7584072","id":"PMC_7584072","title":"The role of IL-2 in gene therapy.","date":"1994","source":"Gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/7584072","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23128233","id":"PMC_23128233","title":"Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease.","date":"2012","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/23128233","citation_count":3725,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"24390342","id":"PMC_24390342","title":"Genetics of rheumatoid arthritis contributes to biology and drug discovery.","date":"2013","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/24390342","citation_count":1778,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8402910","id":"PMC_8402910","title":"Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene.","date":"1993","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/8402910","citation_count":1461,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19430480","id":"PMC_19430480","title":"Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes.","date":"2009","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19430480","citation_count":1382,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"6403867","id":"PMC_6403867","title":"Structure and expression of a cloned cDNA for human interleukin-2.","date":"1983","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/6403867","citation_count":1170,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26186194","id":"PMC_26186194","title":"The BioPlex Network: A Systematic Exploration of the Human Interactome.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26186194","citation_count":1118,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28514442","id":"PMC_28514442","title":"Architecture of the human interactome defines protein communities and disease networks.","date":"2017","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/28514442","citation_count":1085,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21297633","id":"PMC_21297633","title":"Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47.","date":"2011","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/21297633","citation_count":1078,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20453842","id":"PMC_20453842","title":"Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci.","date":"2010","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/20453842","citation_count":1018,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20190752","id":"PMC_20190752","title":"Multiple common variants for celiac disease influencing immune gene expression.","date":"2010","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/20190752","citation_count":801,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8493579","id":"PMC_8493579","title":"Human Sos1: a guanine nucleotide exchange factor for Ras that binds to GRB2.","date":"1993","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/8493579","citation_count":772,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"1830926","id":"PMC_1830926","title":"Development and function of T cells in mice rendered interleukin-2 deficient by gene targeting.","date":"1991","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/1830926","citation_count":756,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"29677473","id":"PMC_29677473","title":"Signaling and Function of Interleukin-2 in T Lymphocytes.","date":"2018","source":"Annual review of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/29677473","citation_count":746,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33961781","id":"PMC_33961781","title":"Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33961781","citation_count":705,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12480696","id":"PMC_12480696","title":"CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity.","date":"2002","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/12480696","citation_count":639,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20596022","id":"PMC_20596022","title":"Genome-wide association study in alopecia areata implicates both innate and adaptive immunity.","date":"2010","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/20596022","citation_count":621,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19073967","id":"PMC_19073967","title":"Shared and distinct genetic variants in type 1 diabetes and celiac disease.","date":"2008","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/19073967","citation_count":566,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8476561","id":"PMC_8476561","title":"The IL-2 receptor complex: its structure, function, and target genes.","date":"1993","source":"Annual review of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/8476561","citation_count":563,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21889323","id":"PMC_21889323","title":"IL-2 family cytokines: new insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation.","date":"2011","source":"Current opinion in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/21889323","citation_count":550,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"7973659","id":"PMC_7973659","title":"Functional activation of Jak1 and Jak3 by selective association with IL-2 receptor subunits.","date":"1994","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/7973659","citation_count":540,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18311140","id":"PMC_18311140","title":"Newly identified genetic risk variants for celiac disease related to the immune response.","date":"2008","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/18311140","citation_count":519,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17558408","id":"PMC_17558408","title":"A genome-wide association study for celiac disease identifies risk variants in the region harboring IL2 and IL21.","date":"2007","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17558408","citation_count":509,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15100259","id":"PMC_15100259","title":"Natural and induced CD4+CD25+ cells educate CD4+CD25- cells to develop suppressive activity: the role of IL-2, TGF-beta, and IL-10.","date":"2004","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/15100259","citation_count":508,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21685912","id":"PMC_21685912","title":"Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy.","date":"2011","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/21685912","citation_count":467,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22446627","id":"PMC_22446627","title":"Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'.","date":"2012","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/22446627","citation_count":461,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"3260003","id":"PMC_3260003","title":"Characterization of antigen receptor response elements within the interleukin-2 enhancer.","date":"1988","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/3260003","citation_count":459,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18275276","id":"PMC_18275276","title":"Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy.","date":"2008","source":"The Journal of infectious diseases","url":"https://pubmed.ncbi.nlm.nih.gov/18275276","citation_count":444,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10072077","id":"PMC_10072077","title":"Stat5 is required for IL-2-induced cell cycle progression of peripheral T cells.","date":"1999","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/10072077","citation_count":442,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15489334","id":"PMC_15489334","title":"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).","date":"2004","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/15489334","citation_count":438,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":41409,"output_tokens":6536,"usd":0.111133},"stage2":{"model":"claude-opus-4-6","input_tokens":10331,"output_tokens":3795,"usd":0.219795},"total_usd":0.707863,"stage1_batch_id":"msgbatch_01DzrsgVgYngY1hvM3DU1yF2","stage2_batch_id":"msgbatch_01KA9b7iRzKFdhoBUT7vCvSe","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":53780,"output_tokens":7214,"usd":0.134775},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":11323,"output_tokens":4193,"usd":0.24216}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1992,\n      \"finding\": \"The gamma chain (γc) of the IL-2 receptor is necessary for formation of high- and intermediate-affinity IL-2 receptors (αβγ heterotrimers and βγ heterodimers, respectively), and is required for IL-2-induced receptor internalization; alpha and beta chains alone are insufficient for internalization.\",\n      \"method\": \"cDNA cloning, receptor reconstitution in murine fibroblastoid cells, internalization assays\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — receptor reconstitution with defined subunit combinations, replicated functional readout (internalization)\",\n      \"pmids\": [\"1631559\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"IL-2 activates STAT5a and STAT5b as one of the earliest signaling events; STAT5 proteins are activated by IL-2 receptor signaling through JAK kinases and regulate target gene expression, with their activity negatively controlled by CIS/SOCS/SSI family proteins.\",\n      \"method\": \"In vitro biochemical studies, in vivo gene-targeting analyses (knockout mice)\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods (biochemical + genetic), replicated across labs\",\n      \"pmids\": [\"10851055\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"IL-2 signals from the receptor to the nucleus via JAK-STAT pathways; mutations in IL-2Rα, γc, and JAK3 cause severe combined immunodeficiency, and IL-2Rβ and γc are shared subunits with other cytokine receptors contributing to cytokine pleiotropy and redundancy.\",\n      \"method\": \"In vitro signaling studies, genetic knockouts in mice, human SCID patient mutation analysis\",\n      \"journal\": \"Cytokine & growth factor reviews\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic and biochemical evidence from multiple systems, replicated\",\n      \"pmids\": [\"9620644\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"IL-2 signaling via STAT5 controls Th1 differentiation by inducing expression of IL-12Rβ2 and T-bet; controls Th2 differentiation by regulating IL-4Rα expression; and inhibits Th17 differentiation by downregulating IL-6Rα and gp130. Retroviral transduction of Il6st rescued Th17 differentiation even in the presence of IL-2, confirming the mechanism.\",\n      \"method\": \"Genetic knockout (Il2-/- mice), retroviral transduction, cytokine receptor expression analysis, antibody blockade\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (KO mice, retroviral rescue, antibody blockade) in single study\",\n      \"pmids\": [\"21516110\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"JAK3 catalytic activity is required in a biphasic manner for IL-2-driven T cell proliferation: an early first wave and a more JAK3-sensitive second wave of STAT5 phosphorylation. Selective inhibition of the second wave blocks cyclin expression and S-phase entry. A covalent JAK3 inhibitor-resistant mutant (C905S) rescued all effects, confirming on-target activity.\",\n      \"method\": \"Selective covalent JAK3 inhibitor, chemical genetics with inhibitor-resistant JAK3 C905S mutant, phospho-STAT5 monitoring over 20h, cell cycle analysis\",\n      \"journal\": \"Nature chemical biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — chemical genetic approach with inhibitor-resistant rescue mutant, mechanistic dissection of temporal signaling\",\n      \"pmids\": [\"27018889\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Crystal structure of basiliximab Fab in complex with IL-2Rα ectodomain at 2.9 Å resolution reveals that basiliximab binds IL-2Rα with 0.14 nM affinity using all six CDR loops, forming a discontinuous epitope on the D1 and D2 domains that overlaps with the IL-2 binding site, thereby completely blocking IL-2/IL-2Rα interaction.\",\n      \"method\": \"X-ray crystallography, binding affinity measurements\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure with functional validation of blocking mechanism\",\n      \"pmids\": [\"20032294\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"De novo designed protein Neo-2/15 mimics IL-2 and IL-15 by binding IL-2Rβγc heterodimer without any binding to IL-2Rα or IL-15Rα, elicits downstream cell signaling independently of these alpha chains, and shows superior therapeutic activity with reduced toxicity. Crystal structures of Neo-2/15 alone and in complex with IL-2Rβγc confirmed the design model.\",\n      \"method\": \"De novo computational protein design, X-ray crystallography, cell signaling assays, mouse tumor models\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure + in vitro signaling + in vivo functional validation in single study\",\n      \"pmids\": [\"30626941\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"PGE2 inhibits IL-2 sensing in human CD8+ tumor-infiltrating lymphocytes via EP2 and EP4 receptors by downregulating the IL-2Rγc chain, resulting in defective assembly of IL-2Rβ-IL-2Rγc membrane dimers, impaired IL-2-mTOR signaling, PGC1α transcriptional repression, oxidative stress, and ferroptotic cell death.\",\n      \"method\": \"Human TIL primary cell experiments, receptor expression analysis, mTOR signaling assays, flow cytometry, in vivo ACT mouse models\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal mechanistic methods in primary human cells with in vivo validation\",\n      \"pmids\": [\"38658764\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"H9T, an engineered IL-2 partial agonist, promotes CD8+ T cell expansion without terminal differentiation by altering STAT5 signaling, sustaining TCF-1 expression, promoting mitochondrial fitness, and maintaining a stem-cell-like transcriptional, epigenetic, and metabolic program distinct from wild-type IL-2.\",\n      \"method\": \"Engineered cytokine variant, STAT5 signaling analysis, transcriptomics, epigenomics, metabolomics, mouse tumor models\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods (signaling, transcriptional, epigenetic, metabolic, in vivo) in single study\",\n      \"pmids\": [\"34526724\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"PTEN inhibits IL-2 receptor-mediated expansion of CD4+CD25+ regulatory T cells by acting as a negative regulator of IL-2R-PI3K signaling. Targeted deletion of PTEN allows Treg expansion in response to IL-2 alone; re-expression of PTEN in PTEN-deficient Tregs or activated CD4+ T cells inhibits IL-2-dependent proliferation.\",\n      \"method\": \"Conditional knockout, re-expression (reintroduction), ex vivo Treg expansion assays, in vivo colitis model\",\n      \"journal\": \"Journal of Clinical Investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal loss- and gain-of-function with defined PI3K signaling mechanism\",\n      \"pmids\": [\"16917540\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Mature splenic dendritic cells express functional IL-2 receptors (including IL-2Rα) and respond to IL-2 by synergistically enhancing IL-12-dependent IFN-γ production; this effect is blocked by anti-IL-2Rα neutralizing antibody. DC produce IFN-γ during interaction with allogeneic CD4+ T cells, suggesting T cell-derived IL-2 acts on DCs during antigen presentation.\",\n      \"method\": \"DC purification, cytokine production assays, neutralizing antibody blockade, Rag-2-/- mice\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — functional IL-2R demonstrated on DCs with receptor blockade, single lab study\",\n      \"pmids\": [\"10820393\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"IL-2 suppression of CYP3A activity in human hepatocytes requires the presence of Kupffer cells; IL-2 alone does not suppress CYP3A in pure hepatocyte cultures, but causes 50-70% suppression in hepatocyte/Kupffer cell cocultures, indicating indirect mechanism through Kupffer cell intermediary signaling.\",\n      \"method\": \"Primary human hepatocyte/Kupffer cell coculture, CYP3A activity assays\",\n      \"journal\": \"Drug metabolism and disposition\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct functional assay with defined cellular mechanism, single lab\",\n      \"pmids\": [\"14977871\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"IL-2 signaling in human monocytes involves phosphorylation and activation of p59hck (a protein tyrosine kinase); IL-2 upregulates hck mRNA and protein, induces p59hck tyrosine phosphorylation, and increases p59hck kinase activity as measured by in vitro kinase assay. PTK inhibitor herbimycin A blocks IL-2-induced monocyte tumoricidal activity and cytokine production.\",\n      \"method\": \"In vitro kinase assay, anti-phosphotyrosine immunoblotting, PTK inhibitor treatment, cytokine mRNA/protein measurements\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro kinase assay with inhibitor validation, single lab\",\n      \"pmids\": [\"10779760\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"ZEB, a zinc finger E-box-binding transcription factor, binds to a negative regulatory element (NRE-A) in the IL-2 promoter and acts as a potent repressor of IL-2 transcription in Th2 cells and partially in Th1 cells.\",\n      \"method\": \"Promoter reporter assays, transcription factor binding studies, T helper cell differentiation assays\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — direct promoter binding demonstrated, single lab\",\n      \"pmids\": [\"9574548\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"NAB2 (NGFI-A-binding protein 2) is induced by TCR engagement and acts as a coactivator for Egr-1 at the IL-2 promoter to enhance IL-2 transcription; NAB2 overexpression increases IL-2 production while siRNA knockdown markedly inhibits it. Chromatin immunoprecipitation shows NAB2 is recruited to the Egr-1 binding site of the IL-2 promoter.\",\n      \"method\": \"Overexpression, siRNA knockdown, chromatin immunoprecipitation (ChIP), reporter assays\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP with gain/loss-of-function, single lab\",\n      \"pmids\": [\"17142725\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"CD28 costimulation of IL-2 production requires translocation of CD28 to lipid rafts; all detectable tyrosine-phosphorylated CD28 localizes to lipid rafts, as does CD28-associated PI3K. Targeting the CD28 cytoplasmic domain to lipid rafts leads to its tyrosine phosphorylation. Analysis of CD28 mutants shows correlation between lipid raft translocation and IL-2 costimulation.\",\n      \"method\": \"Lipid raft fractionation, phosphotyrosine immunoblotting, CD28 mutant analysis, Lck/CD45-deficient Jurkat cells\",\n      \"journal\": \"PNAS\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple biochemical methods with mutant analysis, single lab\",\n      \"pmids\": [\"15280538\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"LFA-1 costimulation upregulates IL-2 gene expression primarily through enhanced IL-2 transcription (not mRNA stabilization), distinct from CD28 costimulation which operates through both transcription and mRNA stabilization. This was shown using an IL-2 promoter-luciferase transgenic reporter and real-time RT-PCR for mRNA stability.\",\n      \"method\": \"IL-2 promoter-luciferase transgenic mice, real-time RT-PCR (mRNA stability), T cell costimulation assays\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — reporter transgene in vivo with molecular mechanistic dissection, single lab\",\n      \"pmids\": [\"11673532\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Truncated Cot kinase (human homolog of tpl-2, a MAP kinase kinase kinase) enhances IL-2 transcription in Jurkat T cells and cooperates with PHA or phorbol ester/calcium ionophore for IL-2 production; a dominant-negative Cot inhibits IL-2 promoter-driven transcription.\",\n      \"method\": \"Reporter gene assays (IL-2 promoter-luciferase), overexpression of truncated and dominant-negative Cot, T cell stimulation assays\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — dominant-negative and overexpression with reporter assay, single lab\",\n      \"pmids\": [\"9257820\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"IL-2 induces STAT5 binding to specific sites in the C-MAF promoter, driving C-MAF expression in human CD4+ T cells. This was demonstrated by chromatin immunoprecipitation; TCR-induced C-MAF expression was inhibited by anti-CD25 antibody (daclizumab) or JAK3 inhibitor, and C-MAF/IL-4 expression in Th2 cells was significantly reduced by IL-2R blockade.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP), daclizumab blockade, JAK3 inhibitor, flow cytometry, cytokine measurement\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP with pharmacological inhibition, single lab\",\n      \"pmids\": [\"21876034\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"IL-2Rβ chains form IL-2-binding homodimers (IL-2Rβ/β) that assemble spontaneously in the absence of γc chain. Co-immunoprecipitation of differentially tagged IL-2Rβ chains, FRET between IL-2Rβ:ECFP and IL-2Rβ:EYFP at living cell surfaces, and 125I-IL-2 binding (Kd ~1 nM) confirm homodimer formation and IL-2 binding.\",\n      \"method\": \"Co-immunoprecipitation, FRET in living cells, radiolabeled IL-2 binding assay\",\n      \"journal\": \"European cytokine network\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (Co-IP, FRET, binding assay), single lab\",\n      \"pmids\": [\"18299274\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"IL-2 producers (cells receiving strongest TCR signals) are fated to become TFH cells while nonproducers (receiving weaker TCR signals) are fated for non-TFH effector functions. IL-2 producers deliver IL-2 in trans to nonproducers, directly linking TCR-signal strength, IL-2 production, and CD4+ T cell fate determination.\",\n      \"method\": \"IL-2 reporter mice (fate-mapping), adoptive transfer, infection models\",\n      \"journal\": \"Science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — reporter mice with fate mapping, single lab\",\n      \"pmids\": [\"30213884\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Anergic T cells contain a dominant-acting repressor molecule that inhibits signal transduction to the IL-2 gene; fusion of anergic T cells with normal T cells or Jurkat cells disrupts IL-2 signaling in the non-anergic partner rather than complementing the anergic defect, indicating dominant repression rather than loss-of-function.\",\n      \"method\": \"T cell heterokaryon fusion assay, IL-2 mRNA induction assay, IL-2 protein detection\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — heterokaryon fusion with trans-dominance demonstrated, single lab\",\n      \"pmids\": [\"9973402\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"PTEN drives Th17 differentiation by suppressing IL-2 production; Th17-specific Pten deletion upregulates IL-2 and STAT5 phosphorylation while reducing STAT3 phosphorylation, impairing Th17 differentiation in vitro and ameliorating EAE in vivo.\",\n      \"method\": \"Conditional Pten knockout (Th17-specific), STAT5/STAT3 phosphorylation analysis, EAE model, PTEN inhibitor\",\n      \"journal\": \"Journal of experimental medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — conditional KO with signaling analysis and in vivo disease model, single lab\",\n      \"pmids\": [\"29018045\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Itk-mediated TCR signaling drives IL-2 production, which in turn activates STAT5 and induces IRF4 expression (via STAT5 binding to the Irf4 promoter) to support Th9 differentiation; IL-2 or constitutively active STAT5 rescue IRF4 and IL-9 expression in Itk-/- T cells.\",\n      \"method\": \"Itk knockout mice, retroviral transduction of constitutively active STAT5, reporter assays, STAT5 binding to Irf4 promoter (implied by STAT5-dependent promoter activity)\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO with cytokine rescue and signaling analysis, single lab\",\n      \"pmids\": [\"26936133\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"TRAF6 in CD4+ T cells limits TGF-β-induced Smad2/3 activation; TRAF6-deficient T cells show enhanced Smad2/3 phosphorylation and more effective TGF-β-mediated suppression of IL-2, which is a known inhibitor of Th17 differentiation, thereby promoting Th17 polarization. Normal Foxp3+ iTreg generation is restored when exogenous IL-2 is supplied.\",\n      \"method\": \"TRAF6 conditional knockout, Smad2/3 phosphorylation analysis, Th17/Treg differentiation assays, IL-2 rescue experiments\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — conditional KO with signaling analysis and cytokine rescue, single lab\",\n      \"pmids\": [\"20351308\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"IL-2 can signal through an alternative pathway involving CD25 and chemokine receptors (independent of canonical JAK1/3-STAT5) to promote Treg suppressive function. An anti-CD25 antibody that biases signaling toward this alternative pathway increased Treg suppressive activity and ameliorated EAE. Heparan sulfate and an engineered IL-2 immunocytokine can also direct signaling through this non-canonical pathway.\",\n      \"method\": \"Biased anti-CD25 antibody, EAE model, engineered IL-2 immunocytokine, Treg suppression assays\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — pharmacological bias with functional readout, single lab\",\n      \"pmids\": [\"37598341\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"IL-2 enhances c-fms (macrophage CSF receptor) mRNA and glycoprotein expression in human monocytes, and macrophage CSF-1 sustains the tumoricidal activity induced by IL-2 (but not IFN-γ), indicating that IL-2 augments monocyte responsiveness to CSF-1 to prolong cytotoxic activity.\",\n      \"method\": \"Northern blot, immunoprecipitation, tumoricidal activity assay, dose-response experiments\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — single lab, mRNA and protein expression with functional correlation but no direct mechanistic dissection\",\n      \"pmids\": [\"2143208\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Lysophosphatidylserine (LysoPS) suppresses IL-2 production in CD4+ T cells via the GPCR LPS3/GPR174; LysoPS had no suppressive effect on splenocytes or CD4+ T cells from LPS3-deficient mice, and LPS3-deficient cells showed increased anti-CD3/CD28-triggered IL-2 production.\",\n      \"method\": \"LPS3-knockout mice, LysoPS treatment, IL-2 mRNA and protein measurement\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — single KO model, single lab, no direct receptor-IL2 promoter mechanistic link\",\n      \"pmids\": [\"29017923\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"IL-2 signals through a tripartite receptor (IL-2Rα/CD25, IL-2Rβ/CD122, γc/CD132) whose assembly requires the γc chain for high/intermediate affinity binding and receptor internalization; ligand binding activates JAK1/JAK3 in a biphasic manner, leading to STAT5 phosphorylation and nuclear translocation, where STAT5 drives transcription of target genes controlling T cell proliferation, survival, and differentiation (Th1 via IL-12Rβ2/T-bet, Th2 via IL-4Rα, inhibition of Th17 via IL-6Rα/gp130 downregulation), while alternative signaling through PI3K/AKT, p59hck, and non-canonical chemokine receptor pathways also contribute to context-specific outcomes including Treg survival, suppressive function, and monocyte activation; IL-2 transcription is regulated by multiple promoter-binding factors including NFAT, NF-κB, Egr-1/NAB2 (co-activators), and ZEB (repressor), with dominant repression occurring in anergic T cells.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1983,\n      \"finding\": \"The human IL-2 cDNA encodes a 153-amino-acid polypeptide including a putative signal sequence; expression of this cDNA in COS cells produced biologically active IL-2, establishing the primary structure of the protein.\",\n      \"method\": \"cDNA cloning, sequencing, and expression in COS cells\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — original molecular cloning with functional validation in heterologous expression system\",\n      \"pmids\": [\"6403867\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1988,\n      \"finding\": \"The IL-2 enhancer contains distinct antigen receptor response elements (sites A, D, E) that are required for maximal IL-2 induction; site E binds an inducible nuclear factor (NF-IL-2E) and site A binds a constitutive T-cell factor (NF-IL-2A); these elements respond to antigen receptor signals independently of PKC stimulation.\",\n      \"method\": \"Deletion mutant analysis, gel-shift/DNA binding assays, reporter gene assays in T cells\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple deletion mutants, functional reporter assays, and DNA-binding experiments in one study\",\n      \"pmids\": [\"3260003\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1991,\n      \"finding\": \"IL-2-deficient mice generated by gene targeting develop normally with respect to thymocyte and peripheral T-cell subset composition, but exhibit reduced polyclonal in vitro T-cell responses and dramatic changes in serum immunoglobulin isotype levels, demonstrating that IL-2 is not required for T-cell development but is required for normal peripheral immune homeostasis.\",\n      \"method\": \"Gene targeting (knockout mice), flow cytometry, in vitro proliferation assays, immunoglobulin measurement\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — definitive in vivo loss-of-function with multiple phenotypic readouts\",\n      \"pmids\": [\"1830926\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"The gamma chain (γc) of the IL-2 receptor was identified as a third subunit necessary for formation of high-affinity (αβγ heterotrimer) and intermediate-affinity (βγ heterodimer) IL-2 receptors; γc is required for IL-2-induced receptor internalization, as α and β chains alone are insufficient.\",\n      \"method\": \"cDNA cloning, receptor reconstitution in murine fibroblastoid cells, binding assays, internalization assays\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — receptor reconstitution with functional internalization assay, foundational paper\",\n      \"pmids\": [\"1631559\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"The IL-2 receptor β chain (IL-2Rβ) contains at least two distinct cytoplasmic signaling regions: a 'serine-rich' region required for mitotic signaling and an 'acidic' region that physically associates with p56lck (a Src-family PTK) and activates it upon IL-2 stimulation, linking IL-2R to c-fos/c-jun and c-myc induction.\",\n      \"method\": \"IL-2Rβ cytoplasmic domain deletion mutants expressed in BAF-B03 cells, co-immunoprecipitation of p56lck, in vitro kinase assays\",\n      \"journal\": \"Annual review of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — structure-function mutagenesis combined with biochemical co-IP and kinase assays\",\n      \"pmids\": [\"8476561\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"IL-2-deficient mice develop an inflammatory bowel disease with clinical and histological similarity to ulcerative colitis, characterized by activated T and B cells, elevated immunoglobulin secretion, and anti-colon antibodies, demonstrating a primary role of IL-2 in preventing aberrant immune responses to intestinal antigens.\",\n      \"method\": \"IL-2 knockout mice, histopathology, flow cytometry, immunoglobulin assays, autoantibody detection\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — definitive in vivo loss-of-function with multiple orthogonal readouts\",\n      \"pmids\": [\"8402910\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"Jak1 and Jak3 kinases are selectively associated with IL-2 receptor subunits: Jak1 binds the serine-rich region of IL-2Rβ and Jak3 binds the C-terminal region of IL-2Rγ; both associations are required for IL-2 signaling, and Jak3-negative cells reconstituted with IL-2R components only become IL-2-responsive upon addition of Jak3 cDNA.\",\n      \"method\": \"Co-immunoprecipitation, domain-mapping with mutant receptor subunits, reconstitution in Jak3-deficient fibroblasts\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstitution experiment in Jak3-deficient cells plus reciprocal co-IP, strong mechanistic evidence\",\n      \"pmids\": [\"7973659\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Stat5a and Stat5b are essential, redundant mediators of IL-2-induced T-cell proliferation and cell cycle progression; Stat5a/b double-knockout mice have peripheral T cells that fail to proliferate or express cell-cycle genes in response to IL-2, and additionally lack NK cells and develop splenomegaly resembling IL-2Rβ-deficient mice.\",\n      \"method\": \"Stat5a/b double-knockout mice, proliferation assays, gene expression analysis, flow cytometry\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — definitive in vivo loss-of-function with multiple phenotypic readouts, replicated across multiple cytokine contexts\",\n      \"pmids\": [\"10072077\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"ZEB, a zinc finger E-box binding transcription factor, represses IL-2 gene transcription in differentiated Th2 cells by binding to a negative regulatory element (NRE-A) in the IL-2 promoter.\",\n      \"method\": \"Promoter deletion analysis, gel-shift assays, reporter gene assays, Th cell differentiation experiments\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — DNA binding demonstrated with gel-shift and promoter reporter assays in differentiated T cells\",\n      \"pmids\": [\"9574548\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"IL-2 signaling activates the JAK-STAT pathway (particularly Stat5a/Stat5b) and other pathways including PI3K/AKT; negative regulation of IL-2-induced Stat5 activation is mediated by CIS/SOCS/SSI family proteins.\",\n      \"method\": \"Biochemical in vitro studies, gene-targeting analyses of Stat5a/Stat5b, cytokine signaling assays\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (biochemistry + in vivo gene targeting) across multiple labs\",\n      \"pmids\": [\"10851055\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"IL-2 directly induces a unique signaling pattern in naive resting CD8+ T cells (TCR-independent): strong LCK/JAK3-dependent PI3K/AKT pathway activation with little involvement of STAT5, NF-κB, or calcineurin/NFAT, resulting in proliferation and selective expression of eomesodermin and differentiation into central memory cells.\",\n      \"method\": \"Purified naive CD8+ T cell culture with IL-2 in absence of Ag/APC, signaling pathway inhibitors, flow cytometry, adoptive transfer\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — clean TCR-independent system with pathway inhibitors and multiple signaling readouts\",\n      \"pmids\": [\"24166977\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"CD28 translocation to lipid rafts is required for costimulation of IL-2 production; all tyrosine-phosphorylated CD28 and CD28 associated with PI3K localize in lipid raft fractions, and targeting the CD28 cytoplasmic domain to lipid rafts is sufficient to induce its tyrosine phosphorylation; murine CD28 mutants defective in raft translocation lose the ability to costimulate IL-2.\",\n      \"method\": \"Lipid raft fractionation, co-immunoprecipitation, CD28 cytoplasmic domain targeting constructs, CD28 mutant analysis in Jurkat and peripheral T cells\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — biochemical fractionation plus mutant analysis with functional IL-2 readout\",\n      \"pmids\": [\"15280538\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"IL-2 suppression of hepatic CYP3A activity in vivo is not a direct effect on hepatocytes but requires Kupffer cells; in hepatocyte/Kupffer cell co-cultures, IL-2 caused 50–70% concentration-dependent suppression of CYP3A activity, whereas hepatocytes alone showed no sustained suppression.\",\n      \"method\": \"Primary human hepatocyte/Kupffer cell co-culture at physiologic ratios, CYP3A activity assays, cytokine dose-response experiments\",\n      \"journal\": \"Drug metabolism and disposition\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — co-culture reconstitution system with quantitative enzyme activity assay\",\n      \"pmids\": [\"14977871\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"PTEN is a negative regulator of IL-2 receptor signaling in regulatory T cells: targeted deletion of PTEN allows Treg expansion in response to IL-2 alone by de-repressing PI3K signaling downstream of the IL-2R, whereas PTEN re-expression in PTEN-deficient cells or in activated CD4+ T cells inhibits IL-2-dependent proliferation.\",\n      \"method\": \"Conditional PTEN knockout in Tregs, ex vivo IL-2-driven expansion assays, PI3K signaling measurement, suppression assays, colitis model\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal gain- and loss-of-function experiments with multiple functional readouts in vitro and in vivo\",\n      \"pmids\": [\"16917540\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"NAB2 is induced by TCR engagement and acts as a co-activator of IL-2 transcription by binding Egr-1 at the IL-2 promoter; NAB2 overexpression enhances IL-2 production, siRNA knockdown markedly inhibits it, and ChIP confirms NAB2 recruitment to the Egr-1 binding site of the IL-2 promoter.\",\n      \"method\": \"siRNA knockdown, overexpression, chromatin immunoprecipitation (ChIP), reporter assays in T cells\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP plus bidirectional genetic manipulation with functional IL-2 readout\",\n      \"pmids\": [\"17142725\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"The crystal structure of the basiliximab Fab in complex with IL-2Rα ectodomain at 2.9 Å resolution reveals that basiliximab uses all six CDR loops to engage a discontinuous epitope spanning the D1 and D2 domains of IL-2Rα, overlapping with most IL-2 contact residues and thereby sterically blocking IL-2 binding to IL-2Rα.\",\n      \"method\": \"X-ray crystallography at 2.9 Å resolution, binding affinity measurements (Kd = 0.14 nM)\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure with direct mechanistic interpretation of receptor blockade\",\n      \"pmids\": [\"20032294\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"IL-2 broadly regulates helper T cell differentiation by modulating cytokine receptor expression via STAT5: IL-2 induces STAT5-dependent expression of IL-12Rβ2 and T-bet to promote Th1 differentiation, regulates Il4ra to promote Th2 differentiation, and inhibits Th17 differentiation by downregulating Il6ra and Il6st (gp130); retroviral transduction of IL-12Rβ2 or Il6st can rescue or augment the respective Th subset differentiation even when IL-2 is present or absent.\",\n      \"method\": \"IL-2 knockout T cells, retroviral transduction, cytokine receptor expression assays, STAT5 reporter, human T cell IL-2 blockade, Th subset differentiation assays\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods including KO, retroviral rescue, and human cell experiments across Th1/Th2/Th17 lineages\",\n      \"pmids\": [\"21516110\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"The IL-2 'superkine' (super-2), engineered with increased IL-2Rβ binding affinity, structurally mimics the CD25-bound conformation of IL-2 by stabilizing a helix at the IL-2Rβ binding site, eliminating the functional requirement for CD25 while eliciting potent STAT5 phosphorylation, T-cell proliferation, superior CD8+ T-cell expansion, and reduced Treg expansion and pulmonary oedema compared to wild-type IL-2.\",\n      \"method\": \"In vitro evolution, crystal structures of free and receptor-bound superkine, molecular dynamics simulations, STAT5 phosphorylation assays, proliferation assays, in vivo mouse tumor models\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structures plus molecular dynamics plus multiple functional assays in one study\",\n      \"pmids\": [\"22446627\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"JAK3 kinase activity is required in two temporally distinct waves during IL-2-driven T cell proliferation: an early wave (sensitive to high JAK3 inhibitor concentrations) and a later, more JAK3-dependent second wave of STAT5 phosphorylation that is essential for cyclin expression and S-phase entry; an inhibitor-resistant JAK3 C905S mutant rescued all effects in isolated T cells and in mice.\",\n      \"method\": \"Selective covalent JAK3 inhibitor, chemical genetic rescue with JAK3 C905S mutant, STAT5 phosphorylation time-course in CD4+ T cells, cell cycle analysis\",\n      \"journal\": \"Nature chemical biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — chemical genetics with inhibitor-resistant mutant rescue, time-resolved mechanistic dissection\",\n      \"pmids\": [\"27018889\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"IL-2 drives CD4+ T follicular helper (TFH) versus non-TFH fate determination through differential IL-2 production at the single-cell level: IL-2 producers receiving the strongest TCR signals are fated to become TFH cells, and they deliver IL-2 in trans to nonproducer cells fated to become non-TFH cells.\",\n      \"method\": \"IL-2 reporter mice, fate-mapping, in vivo infection models, adoptive transfer experiments\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo reporter fate-mapping with mechanistic trans-delivery demonstrated\",\n      \"pmids\": [\"30213884\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"IL-2 signals via the JAK1/3-STAT5 pathway to regulate T-cell metabolic programs in addition to transcriptional programs; global phosphoproteomic approaches revealed a diverse array of phosphoproteins influenced by IL-2 that shape T cell fate within each subset.\",\n      \"method\": \"Phosphoproteomics, JAK inhibitor studies, metabolic assays, T-cell subset analysis\",\n      \"journal\": \"Annual review of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — phosphoproteomic approach integrated with functional metabolic assays\",\n      \"pmids\": [\"29677473\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"De novo designed IL-2/IL-15 mimetics (Neoleukin-2/15, Neo-2/15) bind IL-2Rβγc with higher affinity than natural IL-2 and elicit downstream signaling without any IL-2Rα binding site; crystal structures of Neo-2/15 alone and in complex with IL-2Rβγc confirmed the designed topology, and Neo-2/15 showed superior antitumour activity in mouse models with reduced toxicity.\",\n      \"method\": \"Computational protein design, crystal structures (free and receptor-bound), binding assays, cell signaling assays, in vivo mouse melanoma and colon cancer models\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structures plus reconstituted receptor binding plus in vivo functional validation\",\n      \"pmids\": [\"30626941\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"H9T, an engineered IL-2 partial agonist, promotes CD8+ T cell expansion without terminal differentiation by generating altered (attenuated) STAT5 signaling, sustaining TCF-1 expression, and promoting mitochondrial fitness, resulting in a stem-cell-like T cell state with enhanced antitumour activity in melanoma and ALL mouse models.\",\n      \"method\": \"Engineered IL-2 variant, STAT5 signaling assays, epigenetic profiling, metabolic assays, TCF-1 expression analysis, in vivo mouse tumor models\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal mechanistic readouts (signaling, epigenetics, metabolism, in vivo efficacy) in a single well-controlled study\",\n      \"pmids\": [\"34526724\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"IL-2 can signal through a non-canonical CD25–chemokine receptor pathway (alternative to the canonical JAK1/3-STAT5 axis) to promote the suppressive function of Tregs; biasing IL-2 signaling toward this alternative pathway using a specific anti-CD25 antibody, heparan sulfate, or an engineered IL-2 immunocytokine increases Treg suppressive activity and ameliorates EAE in mice.\",\n      \"method\": \"Biased anti-CD25 antibody, heparan sulfate treatment, engineered IL-2 immunocytokine, EAE mouse model, Treg suppression assays\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple tools to bias signaling pathway with functional Treg and in vivo disease readouts\",\n      \"pmids\": [\"37598341\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"PGE2, via its receptors EP2 and EP4, inhibits IL-2 sensing in human CD8+ TILs by downregulating the IL-2Rγc chain, causing defective assembly of IL-2Rβ–IL-2Rγc membrane dimers; this impairs IL-2–mTOR adaptation, represses PGC1α transcription, causes oxidative stress and ferroptotic cell death in tumour-reactive TILs; blocking EP2/EP4 during TIL expansion restores IL-2 sensing and antitumour efficacy.\",\n      \"method\": \"PGE2/EP2/EP4 receptor pharmacology, IL-2Rγc surface expression measurement, IL-2Rβ–γc dimer assembly assays, mTOR signaling assays, PGC1α expression, ROS/ferroptosis assays, adoptive cell transfer mouse models\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mechanistically layered dissection with multiple orthogonal assays and in vivo validation\",\n      \"pmids\": [\"38658764\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"IL-2Rβ chains can spontaneously form homodimers (IL-2Rβ/β) in the absence of γc, as demonstrated by co-immunoprecipitation of differentially tagged IL-2Rβ subunits and FRET between fluorescent reporter-fused IL-2Rβ chains at the cell surface; these homodimers bind IL-2 with Kd ~1 nM, similar to IL-2Rβ/γc heterodimers.\",\n      \"method\": \"Co-immunoprecipitation (HA/MYC-tagged co-transfection), FRET between ECFP/EYFP-fused IL-2Rβ, 125I-IL-2 binding assays\",\n      \"journal\": \"European cytokine network\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal co-IP plus FRET in live cells plus functional binding assay\",\n      \"pmids\": [\"18299274\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"IL-2 signaling in human monocytes requires protein tyrosine kinase activity and specifically involves phosphorylation and activation of p59hck (Hck); herbimycin A (PTK inhibitor) abolishes IL-2-induced monocyte tumoricidal activity and cytokine production; IL-2 upregulates hck mRNA/protein and increases p59hck tyrosine phosphorylation and kinase activity in vitro.\",\n      \"method\": \"PTK inhibitor (herbimycin A), anti-phosphotyrosine immunoblotting, in vitro kinase assay, RT-PCR, cytotoxicity assay\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro kinase assay plus multiple signaling readouts with pharmacological inhibition\",\n      \"pmids\": [\"10779760\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"LFA-1 costimulation of IL-2 gene expression is mediated primarily through enhanced IL-2 transcription (not mRNA stabilization), as shown using an IL-2 promoter-luciferase transgenic reporter; in contrast, CD28 costimulation enhances both transcription and mRNA stability.\",\n      \"method\": \"IL-2 promoter-luciferase transgenic mice, real-time RT-PCR for mRNA stability, antigen-presenting cell lines with/without ICAM-1 or B7-1\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — dissection of transcriptional vs. post-transcriptional mechanisms with transgenic reporter and mRNA stability assay\",\n      \"pmids\": [\"11673532\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"PTEN drives Th17 cell differentiation by suppressing IL-2 production; Th17-specific Pten deletion increases IL-2 and STAT5 phosphorylation while reducing STAT3 phosphorylation, thereby inhibiting Th17 differentiation in vitro and ameliorating EAE; PTEN inhibitors phenocopy Th17 suppression.\",\n      \"method\": \"Conditional Th17-specific Pten knockout mice, IL-2 ELISA, STAT5/STAT3 phosphorylation assays, EAE model, PTEN inhibitor experiments\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — conditional KO with in vivo disease model plus pharmacological corroboration and defined signaling mechanism\",\n      \"pmids\": [\"29018045\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"CD56bright NK cells in human lymph nodes constitutively express the high-affinity IL-2 receptor and respond to endogenous T cell-derived IL-2 by secreting IFN-γ, establishing a direct mechanistic link between adaptive T cell-derived IL-2 and innate NK cell cytokine production.\",\n      \"method\": \"In situ hybridization, flow cytometry, lymph node NK cell isolation, IL-2 neutralization experiments, IFN-γ assays\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct neutralization of endogenous IL-2 with functional IFN-γ readout in primary human cells\",\n      \"pmids\": [\"12480696\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"IL-2 is a secreted cytokine whose primary structure was established by cDNA cloning; it binds a trimeric receptor (IL-2Rα/β/γc) where γc is required for internalization, Jak1 associates with the serine-rich region of IL-2Rβ and Jak3 with IL-2Rγc to activate STAT5 (redundantly via Stat5a/b) and PI3K/AKT signaling; STAT5 then broadly regulates helper T-cell fate by modulating cytokine receptor expression (IL-12Rβ2, IL-4Rα, gp130), while negative regulators including SOCS proteins, PTEN, ZEB, and PGE2 (acting through EP2/EP4-mediated downregulation of IL-2Rγc) control the magnitude of IL-2 signaling; in vivo, IL-2 is essential for regulatory T-cell development and peripheral tolerance (not T-cell thymic development), and engineered IL-2 variants with altered receptor subunit affinities selectively bias signaling toward CD8+ effector T cells or Tregs for therapeutic purposes.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"IL-2 is a pleiotropic cytokine that serves as a central regulator of adaptive immune cell proliferation, differentiation, and tolerance. It signals through a heterotrimeric receptor composed of IL-2Rα (CD25), IL-2Rβ (CD122), and the common γ chain (γc/CD132), where γc is essential for high- and intermediate-affinity receptor assembly and ligand-induced internalization [PMID:1631559]; ligand engagement activates JAK1/JAK3 in a biphasic manner, with a second, more JAK3-sensitive wave of STAT5 phosphorylation required for cyclin induction and S-phase entry [PMID:27018889, PMID:10851055]. STAT5 activation downstream of IL-2 governs CD4+ T helper fate by inducing IL-12Rβ2/T-bet (Th1), IL-4Rα (Th2), IRF4 (Th9), and C-MAF (Th2), while suppressing Th17 differentiation through downregulation of IL-6Rα/gp130 [PMID:21516110, PMID:26936133, PMID:21876034]. IL-2 also signals through PI3K/AKT to control regulatory T cell expansion—negatively gated by PTEN [PMID:16917540]—and an alternative non-canonical pathway via CD25 and chemokine receptors that promotes Treg suppressive function independently of JAK-STAT5 [PMID:37598341].\",\n  \"teleology\": [\n    {\n      \"year\": 1992,\n      \"claim\": \"Defining the minimal receptor subunit requirements resolved how IL-2 receptor affinity classes are assembled and showed that γc is indispensable for both high-/intermediate-affinity binding and signal-competent internalization.\",\n      \"evidence\": \"Receptor reconstitution with defined subunit combinations in murine fibroblastoid cells with internalization assays\",\n      \"pmids\": [\"1631559\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis for γc contribution to receptor assembly not yet determined\", \"Whether γc-independent IL-2Rβ homodimers are physiologically relevant remained unaddressed\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Establishing that IL-2 receptor signals converge on JAK-STAT pathways—and that mutations in γc and JAK3 cause SCID—linked cytokine signaling to lymphocyte development and explained cytokine redundancy through shared receptor subunits.\",\n      \"evidence\": \"Human SCID patient mutation analysis combined with in vitro signaling and mouse genetic knockouts\",\n      \"pmids\": [\"9620644\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contributions of individual STAT family members downstream of IL-2 were not yet dissected\", \"Downstream transcriptional targets of IL-2-activated STATs in vivo were unknown\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Identification of transcriptional regulators of the IL-2 gene—ZEB as a repressor via the NRE-A element, and later NAB2/Egr-1 as a coactivator complex, Cot kinase as a MAPKKK activator, and a dominant repressor in anergic T cells—defined the logic of IL-2 gene control in effector versus tolerant T cells.\",\n      \"evidence\": \"Promoter-reporter assays with transcription factor binding studies (ZEB), ChIP with gain/loss-of-function (NAB2), dominant-negative approaches (Cot), and heterokaryon fusion assays (anergy)\",\n      \"pmids\": [\"9574548\", \"17142725\", \"9257820\", \"9973402\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Identity of the dominant anergic repressor molecule was not determined\", \"How ZEB, NAB2/Egr-1, NFAT, and NF-κB integrate combinatorially at the IL-2 promoter remains incompletely mapped\", \"Chromatin-level regulation at the endogenous IL-2 locus was not addressed\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Biochemical and genetic evidence established STAT5a/b as the earliest critical IL-2 effectors, with CIS/SOCS proteins providing negative feedback, defining the core signal relay from receptor to nucleus.\",\n      \"evidence\": \"In vitro biochemistry and STAT5 knockout mice\",\n      \"pmids\": [\"10851055\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative in vivo roles of STAT5a versus STAT5b downstream of IL-2 not fully separated\", \"Genome-wide STAT5 target genes in IL-2-stimulated cells not yet mapped\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Costimulatory signals from CD28 and LFA-1 were shown to regulate IL-2 production through distinct mechanisms—CD28 via lipid raft-dependent PI3K signaling affecting both transcription and mRNA stability, and LFA-1 primarily through transcriptional enhancement—revealing that multiple upstream inputs converge on IL-2 expression through separable pathways.\",\n      \"evidence\": \"Lipid raft fractionation with CD28 mutant analysis in Jurkat cells; IL-2 promoter-luciferase transgenic mice with mRNA stability measurements\",\n      \"pmids\": [\"15280538\", \"11673532\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Specific transcription factors activated by LFA-1 at the IL-2 promoter were not identified\", \"Whether lipid raft recruitment of CD28 is sufficient or merely correlative for IL-2 induction was not fully resolved\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"PTEN was identified as a gatekeeper of IL-2-driven Treg expansion by negatively regulating IL-2R-PI3K/AKT signaling, establishing the PI3K axis as a distinct IL-2 effector pathway parallel to JAK-STAT in regulatory T cells.\",\n      \"evidence\": \"Conditional PTEN knockout with reciprocal re-expression, ex vivo Treg expansion, and in vivo colitis model\",\n      \"pmids\": [\"16917540\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream PI3K targets specific to IL-2-driven Treg expansion were not identified\", \"Whether PTEN regulation of IL-2 signaling differs between Tregs and effector T cells was not fully addressed\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"The crystal structure of basiliximab Fab bound to IL-2Rα revealed the precise molecular surface used for IL-2 binding on the receptor, providing a structural template for therapeutic IL-2R blockade.\",\n      \"evidence\": \"X-ray crystallography at 2.9 Å with binding affinity measurements\",\n      \"pmids\": [\"20032294\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structure of the complete IL-2/IL-2Rαβγ quaternary complex was not obtained in this study\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"IL-2/STAT5 signaling was shown to be a master switch for T helper fate: it promotes Th1 (via IL-12Rβ2/T-bet) and Th2 (via IL-4Rα and C-MAF), while suppressing Th17 by downregulating IL-6Rα/gp130—unifying IL-2's pleiotropic effects on helper lineage commitment through a single transcription factor.\",\n      \"evidence\": \"Il2-/- mice, retroviral rescue of gp130, antibody blockade, ChIP for STAT5 at C-MAF promoter, daclizumab/JAK3 inhibitor blockade\",\n      \"pmids\": [\"21516110\", \"21876034\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How IL-2/STAT5 dosage quantitatively biases Th1 versus Th2 commitment is unresolved\", \"Epigenetic mechanisms downstream of STAT5 at helper lineage loci not defined\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Chemical genetic dissection revealed that JAK3 catalytic activity is required in two temporal waves for IL-2-driven proliferation, with the second wave being more sensitive and essential for cyclin induction and S-phase entry—establishing a biphasic signaling model.\",\n      \"evidence\": \"Selective covalent JAK3 inhibitor with C905S inhibitor-resistant rescue mutant, phospho-STAT5 kinetics over 20 h, cell cycle analysis\",\n      \"pmids\": [\"27018889\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"What distinguishes the molecular targets of the first versus second wave of STAT5 activation is unknown\", \"Whether biphasic JAK3 signaling applies to all IL-2-responsive cell types was not tested\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Fate-mapping in vivo showed that TCR signal strength determines which CD4+ T cells produce IL-2 (strongest signals → TFH fate) versus consume it (weaker signals → non-TFH effectors), establishing IL-2 as a paracrine mediator linking signal strength to lineage choice.\",\n      \"evidence\": \"IL-2 reporter fate-mapping mice with adoptive transfer and infection models\",\n      \"pmids\": [\"30213884\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular mechanism linking high TCR signal strength to preferential IL-2 transcription not defined\", \"Whether this paracrine model applies to chronic infection or tumor settings is untested\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"De novo designed mimetic Neo-2/15, which binds IL-2Rβγc without engaging IL-2Rα, recapitulated downstream signaling and showed superior therapeutic efficacy with reduced toxicity—demonstrating that the α chain is dispensable for core signaling and that receptor geometry determines biological outcome.\",\n      \"evidence\": \"Computational protein design, crystal structures of Neo-2/15 alone and in complex with IL-2Rβγc, signaling assays, mouse tumor models\",\n      \"pmids\": [\"30626941\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Long-term immunological consequences of α-independent IL-2R signaling in vivo not characterized\", \"Whether Neo-2/15 differentially affects Treg versus effector T cell homeostasis at physiological doses is unclear\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"An engineered IL-2 partial agonist (H9T) demonstrated that quantitative tuning of STAT5 signal strength controls whether CD8+ T cells undergo terminal differentiation or maintain a stem-cell-like program, linking IL-2 signaling amplitude to epigenetic and metabolic cell fate.\",\n      \"evidence\": \"Engineered cytokine variant with transcriptomic, epigenomic, metabolomic, and in vivo tumor model analyses\",\n      \"pmids\": [\"34526724\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Precise STAT5 target genes that distinguish partial from full agonism are not defined\", \"Whether partial agonism similarly modulates CD4+ T cell or Treg programs is untested\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Discovery of a non-canonical IL-2 signaling pathway through CD25 and chemokine receptors—independent of JAK1/3-STAT5—that specifically enhances Treg suppressive function expanded the signaling repertoire beyond the classical JAK-STAT model.\",\n      \"evidence\": \"Biased anti-CD25 antibody, EAE disease model, engineered IL-2 immunocytokine, Treg suppression assays\",\n      \"pmids\": [\"37598341\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"The chemokine receptor(s) involved and downstream signaling intermediates are not identified\", \"Whether this pathway operates physiologically or only under pharmacological bias is unclear\", \"Independent replication in another lab is needed\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"PGE2 was shown to suppress IL-2 sensing in tumor-infiltrating CD8+ T cells by downregulating γc, disrupting IL-2Rβ-γc dimer assembly, and consequently impairing mTOR signaling—leading to ferroptotic cell death—revealing a mechanism of immune evasion in the tumor microenvironment.\",\n      \"evidence\": \"Primary human TIL experiments, receptor expression and mTOR signaling analysis, in vivo adoptive cell transfer mouse models\",\n      \"pmids\": [\"38658764\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether γc downregulation by PGE2 affects other γc-dependent cytokines (IL-7, IL-15, IL-21) in TILs is not addressed\", \"Transcriptional versus post-translational mechanism of γc downregulation not defined\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the identity and mechanism of the dominant repressor active in anergic T cells, the structural basis of biphasic JAK3 signaling, the specific chemokine receptors mediating non-canonical IL-2/CD25 signaling, and how graded STAT5 amplitude is decoded into distinct transcriptional and epigenetic programs across different T cell subsets.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Identity of dominant anergic repressor unknown\", \"Structural basis for biphasic JAK3 activation not resolved\", \"Chemokine receptor partners in non-canonical CD25 pathway not identified\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [0, 3, 6, 7, 8]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [3, 20, 23]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [3, 6, 20]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0162582\", \"supporting_discovery_ids\": [1, 2, 4, 9, 25]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [1, 3, 7, 8, 9, 20, 23]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [1, 2, 4, 9, 25]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [4, 8]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"IL2RA\",\n      \"IL2RB\",\n      \"IL2RG\",\n      \"JAK3\",\n      \"STAT5A\",\n      \"STAT5B\",\n      \"PTEN\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"IL-2 is a secreted cytokine that orchestrates peripheral immune homeostasis by driving T-cell proliferation, directing helper T-cell fate decisions, sustaining regulatory T-cell function, and bridging adaptive and innate immunity through NK cell activation. IL-2 signals through a trimeric receptor (IL-2Rα/β/γc), where γc is essential for receptor internalization and high-affinity binding [PMID:1631559]; ligand engagement activates Jak1 (via the IL-2Rβ serine-rich region) and Jak3 (via γc) to phosphorylate STAT5a/b redundantly, which in turn modulates cytokine receptor expression (IL-12Rβ2, IL-4Rα, gp130) to broadly regulate Th1, Th2, and Th17 lineage commitment [PMID:7973659, PMID:10072077, PMID:21516110]. IL-2 also activates PI3K/AKT signaling, negatively regulated by PTEN and SOCS/CIS family proteins, and signal strength is tuned by PGE2-mediated downregulation of γc on tumor-infiltrating lymphocytes, linking prostaglandin metabolism to IL-2 sensing and ferroptotic vulnerability [PMID:10851055, PMID:16917540, PMID:38658764]. IL-2-deficient mice are not impaired in thymic T-cell development but develop inflammatory bowel disease resembling ulcerative colitis, establishing IL-2 as essential for peripheral tolerance rather than lymphocyte ontogeny [PMID:1830926, PMID:8402910].\",\n  \"teleology\": [\n    {\n      \"year\": 1983,\n      \"claim\": \"Molecular cloning of the human IL-2 cDNA established the primary structure of the protein and proved that the cloned sequence was sufficient for biological activity, enabling all subsequent structure–function work.\",\n      \"evidence\": \"cDNA cloning, sequencing, and functional expression in COS cells\",\n      \"pmids\": [\"6403867\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"post-translational modifications not characterized\", \"receptor identity unknown at this point\"]\n    },\n    {\n      \"year\": 1988,\n      \"claim\": \"Identification of distinct antigen receptor response elements (sites A, D, E) and their cognate transcription factors in the IL-2 enhancer revealed how TCR engagement transcriptionally activates IL-2 independently of PKC, establishing the promoter architecture governing inducible IL-2 expression.\",\n      \"evidence\": \"Deletion mutant analysis, gel-shift assays, and reporter gene assays in T cells\",\n      \"pmids\": [\"3260003\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"identity of all trans-acting factors not resolved\", \"chromatin-level regulation not addressed\"]\n    },\n    {\n      \"year\": 1991,\n      \"claim\": \"IL-2 knockout mice demonstrated that IL-2 is dispensable for thymic T-cell development but essential for peripheral immune homeostasis, reframing IL-2 from a T-cell growth factor to a tolerance regulator.\",\n      \"evidence\": \"Gene-targeted IL-2-null mice with flow cytometry, proliferation assays, and immunoglobulin measurements\",\n      \"pmids\": [\"1830926\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"mechanism of peripheral tolerance breakdown not defined\", \"contribution of Tregs not yet recognized\"]\n    },\n    {\n      \"year\": 1992,\n      \"claim\": \"Discovery of γc as the third IL-2R subunit resolved how high-affinity and intermediate-affinity receptor forms assemble and showed that γc is required for ligand-induced receptor internalization, completing the receptor architecture.\",\n      \"evidence\": \"cDNA cloning, receptor reconstitution in fibroblastoid cells, binding and internalization assays\",\n      \"pmids\": [\"1631559\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"signaling events downstream of γc not yet mapped\", \"shared use of γc by other cytokines not explored here\"]\n    },\n    {\n      \"year\": 1993,\n      \"claim\": \"Mapping of IL-2Rβ cytoplasmic domains identified a serine-rich region for mitogenic signaling and an acidic region that recruits p56lck, linking IL-2R to Src-family kinase activation and immediate-early gene induction, while IL-2-null mice developed ulcerative colitis-like disease, cementing IL-2's role in mucosal tolerance.\",\n      \"evidence\": \"IL-2Rβ deletion mutants with co-IP and kinase assays; IL-2 KO mice with histopathology and autoantibody detection\",\n      \"pmids\": [\"8476561\", \"8402910\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"identity of kinases directly activated by the serine-rich region not yet known\", \"Treg mechanism of tolerance not established\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Demonstrating that Jak1 binds IL-2Rβ and Jak3 binds γc—and that Jak3 reconstitution restores IL-2 responsiveness—established the proximal kinase pair that initiates IL-2 signaling cascades.\",\n      \"evidence\": \"Co-IP domain mapping plus reconstitution of Jak3 in Jak3-deficient fibroblasts\",\n      \"pmids\": [\"7973659\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"temporal dynamics of Jak1 vs Jak3 activation unclear\", \"downstream substrate hierarchy not defined\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Identification of ZEB as a repressor of IL-2 transcription in Th2 cells via the NRE-A element revealed a lineage-specific negative regulatory mechanism silencing IL-2 during T-helper differentiation.\",\n      \"evidence\": \"Promoter deletion analysis, gel-shift assays, reporter assays in differentiated Th cells\",\n      \"pmids\": [\"9574548\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"in vivo relevance of ZEB-mediated repression not confirmed with knockout\", \"interaction with other promoter-bound factors not mapped\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Stat5a/b double-knockout mice proved that STAT5 is the essential, redundant downstream effector of IL-2-induced T-cell proliferation and cell-cycle entry, phenocopying IL-2Rβ deficiency.\",\n      \"evidence\": \"Stat5a/b double-KO mice with proliferation assays, gene expression analysis, and flow cytometry\",\n      \"pmids\": [\"10072077\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"STAT5-independent IL-2 signaling outputs not fully cataloged\", \"direct STAT5 transcriptional targets in T cells not genome-wide mapped at this point\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Integration of biochemical and genetic data consolidated the JAK-STAT5 and PI3K/AKT axes as the principal IL-2 signaling pathways, with CIS/SOCS proteins identified as negative feedback regulators of STAT5 activation.\",\n      \"evidence\": \"Biochemical signaling assays, gene-targeting analyses, cytokine dose-response studies\",\n      \"pmids\": [\"10851055\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"relative contribution of each SOCS family member not individually resolved\", \"metabolic consequences of PI3K/AKT activation downstream of IL-2 not yet defined\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"PTEN was established as a key negative regulator of IL-2R-driven PI3K signaling in Tregs, with its deletion enabling IL-2-alone-driven Treg expansion, revealing a tunable brake on the IL-2/PI3K/AKT axis that governs Treg homeostasis.\",\n      \"evidence\": \"Conditional PTEN KO in Tregs with reciprocal gain/loss-of-function experiments, PI3K signaling, and in vivo colitis model\",\n      \"pmids\": [\"16917540\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"PTEN interaction with SOCS-mediated STAT5 regulation not addressed\", \"Treg-specific vs pan-T-cell PTEN effects not fully delineated\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"IL-2 was shown to broadly control helper T-cell fate by STAT5-dependent modulation of cytokine receptor chains (IL-12Rβ2, IL-4Rα, gp130), promoting Th1 and Th2 while suppressing Th17 differentiation—redefining IL-2 as a master regulator of T-helper lineage commitment.\",\n      \"evidence\": \"IL-2 KO T cells, retroviral transduction rescue, cytokine receptor expression profiling, human T-cell IL-2 blockade\",\n      \"pmids\": [\"21516110\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"epigenetic mechanisms linking STAT5 to receptor gene regulation not resolved\", \"quantitative thresholds of IL-2 needed for each lineage decision unknown\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Structural and functional characterization of 'super-2' (an engineered high-affinity IL-2Rβ binder) demonstrated that stabilizing the CD25-bound conformation of IL-2 eliminates CD25 dependence, biasing signaling toward CD8+ effector expansion over Treg expansion—establishing the principle of receptor-biased IL-2 engineering.\",\n      \"evidence\": \"Crystal structures of free and receptor-bound superkine, molecular dynamics, signaling and proliferation assays, in vivo tumor models\",\n      \"pmids\": [\"22446627\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"long-term immunological consequences of bypassing CD25 not assessed\", \"toxicity mechanisms beyond pulmonary edema not explored\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Chemical genetic dissection revealed two temporally distinct JAK3-dependent waves of STAT5 phosphorylation during IL-2-driven proliferation, with the second wave essential for cyclin expression and S-phase entry, refining the kinetic model of IL-2 signaling.\",\n      \"evidence\": \"Covalent JAK3 inhibitor with inhibitor-resistant C905S mutant rescue, time-resolved STAT5 phosphorylation, cell-cycle analysis\",\n      \"pmids\": [\"27018889\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"molecular basis for differential JAK3 sensitivity of the two waves unclear\", \"whether this biphasic pattern applies to all T-cell subsets untested\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"In vivo fate-mapping showed that IL-2-producing CD4+ T cells receiving the strongest TCR signals become TFH cells, while non-producers receiving IL-2 in trans become non-TFH effectors, establishing a paracrine delivery model for IL-2-driven fate divergence.\",\n      \"evidence\": \"IL-2 reporter mice, fate-mapping, infection models, adoptive transfer\",\n      \"pmids\": [\"30213884\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"molecular mechanism of trans-delivery (synapse vs diffusion) not resolved\", \"generalizability beyond infection models not tested\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"De novo computational design of Neo-2/15, a synthetic IL-2/IL-15 mimetic with no sequence or structural homology to natural cytokines, demonstrated that IL-2Rβγc engagement alone—without any IL-2Rα contact—suffices for potent signaling and superior antitumor activity with reduced toxicity.\",\n      \"evidence\": \"Crystal structures (free and receptor-bound), binding assays, cell signaling, mouse melanoma and colon cancer models\",\n      \"pmids\": [\"30626941\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"human clinical translation and immunogenicity not assessed\", \"whether Neo-2/15 engages non-canonical IL-2 signaling pathways unknown\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"The IL-2 partial agonist H9T showed that attenuated STAT5 signaling preserves TCF-1 expression and mitochondrial fitness in CD8+ T cells, generating stem-cell-like effectors with enhanced antitumor activity—demonstrating that signal strength, not just pathway identity, determines T-cell differentiation outcome.\",\n      \"evidence\": \"Engineered IL-2 variant with STAT5 signaling, epigenetic profiling, metabolic assays, in vivo tumor models\",\n      \"pmids\": [\"34526724\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"epigenetic mechanisms linking attenuated STAT5 to TCF-1 maintenance not defined\", \"durability of stem-like state after withdrawal of H9T not tested\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Discovery of a non-canonical IL-2 signaling mode through CD25 and a chemokine receptor pathway—distinct from JAK1/3-STAT5—that specifically enhances Treg suppressive function revealed an unexpected layer of signaling complexity exploitable for selective immunomodulation.\",\n      \"evidence\": \"Biased anti-CD25 antibody, heparan sulfate treatment, engineered IL-2 immunocytokine, EAE model, Treg suppression assays\",\n      \"pmids\": [\"37598341\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"identity and mechanism of the chemokine receptor component not fully defined\", \"whether this pathway operates in human Tregs in vivo not demonstrated\", \"independent replication needed\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"PGE2 was shown to impair IL-2 sensing in tumor-infiltrating CD8+ T cells by EP2/EP4-mediated downregulation of γc, disrupting IL-2Rβ–γc dimer assembly and causing mTOR-PGC1α failure, oxidative stress, and ferroptosis—linking the tumor prostaglandin microenvironment directly to IL-2 signaling resistance.\",\n      \"evidence\": \"EP2/EP4 pharmacology, γc surface expression and dimer assembly assays, mTOR/PGC1α/ROS/ferroptosis assays, adoptive cell transfer models\",\n      \"pmids\": [\"38658764\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"whether PGE2-driven γc loss affects other γc-dependent cytokines in TILs not tested\", \"mechanism of EP2/EP4-mediated γc transcriptional or post-translational downregulation not resolved\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key open questions include: (1) the structural and kinetic basis for non-canonical IL-2 signaling through CD25/chemokine receptor pathways; (2) how IL-2 signal strength is decoded epigenetically to produce distinct T-cell differentiation and metabolic programs; and (3) whether therapeutic IL-2 variants can be designed to independently tune STAT5 vs PI3K/AKT vs non-canonical outputs for precision immunotherapy.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"no structural model of the non-canonical signaling complex exists\", \"genome-wide STAT5 target gene sets in specific T-cell subsets at defined IL-2 concentrations not available\", \"clinical translation data for biased IL-2 variants remain limited\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [0, 3, 17, 21]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 19]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [1, 8, 14]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [2, 5, 7, 16, 19, 24]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [6, 9, 13, 17, 18, 22, 23]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"IL2RA\",\n      \"IL2RB\",\n      \"IL2RG\",\n      \"JAK1\",\n      \"JAK3\",\n      \"STAT5A\",\n      \"STAT5B\",\n      \"PTEN\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}